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Abstract 
Several techniques utilizing multimodal brain image processing and analysis as a 
potential means of improving diagnostic outcomes in recurrent glioma and 
Alzheimer’s disease (AD) have been investigated. 
 
Treatment for late stage glioma involves surgery and chemo-radiotherapy which 
causes necrosis and oedema that can be mistaken for, or mask, cancer recurrence. 
Two positron emission tomography (PET) imaging isotopes (
11
Carbon-Methionine 
(CMET) and 3’-deoxy-3’-18Fluorine-fluorothymidine (FLT)) were investigated with 
regards to the ideal length of time that should elapse between isotope administration 
and imaging in a cohort of post-treatment late stage glioma patients in order to 
maximise tumour-healthy tissue contrast. It was found that the ideal times to 
commence post-administration imaging using CMET and FLT were less than 40 and 
75 minutes respectively. The same patient cohort was then used to test the capacity 
of CMET and FLT-PET as well as Gadolinium enhanced T1 weighted magnetic 
resonance imaging (Gd-MRI) to act as a survival predictor, based on the volume of 
tissue that demonstrated substantially elevated uptake/enhancement. CMET was the 
only significant predictor of survival (p<0.05, Log-Rank test).  
 
Inter-subject variability and the nonlinear fashion in which AD symptoms develop 
make definitive early diagnosis very difficult. In vivo brain image analysis could 
increase diagnostic accuracy by identifying characteristic patterns of AD physiology. 
A study was conducted to compare an optimised automated volumetric hippocampal 
mask with one that was manually defined and assessed their utility in separating 
groups of healthy control (HC), mildly cognitively impaired (MCI), and AD brains 
based on hippocampal metabolism as seen on 2-Deoxy-2-[
18
F]fluoroglucose (FDG)-
PET. Both masks were able to find significant differences between the AD and MCI 
(p < 0.005) and AD and HC (p < 0.0005) groups, but not the MCI and HC groups 
using Tukey’s HSD test. The automated mask was then evaluated with regards to its 
potential utility as a clinical diagnostic tool; it was found that it would likely find 
greatest value as a means of screening patients in order to flag those with very low 
hippocampal metabolism as having an increased risk of AD. 
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1 Introduction and Literature Review 
 
1.1 Overview 
 
Disease pathology of the brain was historically difficult to observe in vivo, due to the 
requirement to penetrate the skull in order to expose the brain, and the extremely 
high stakes involved in any attempt at physical intervention in the cranial region. The 
advent of x-ray, magnetic resonance imaging (MRI), and various nuclear medicine 
imaging methods have completely changed the manner in which diseases of the brain 
can be observed and treated. This thesis presents image analysis techniques to aid in 
the identification and treatment of two brain conditions: glioma and Alzheimer’s 
disease (AD). 
 
Glioma, and in particular glioblastoma multiforme, is a tumour type that is notorious 
for its low rates of long term treatment efficacy. Treatment is almost always followed 
by recurrence due to the aggressive radial  growth patterns of the disease and the 
difficulty associated with complete lesion removal (Fortin 2011). Novel brain 
imaging methodologies and image processing techniques are avenues of research that 
aim to increase spatial accuracy of lesion identification and deliver higher sensitivity 
and specificity with respect to the detection of recurrent cancer growth. In this thesis, 
the optimal post-injection delay time for imaging of post-treatment glioma patients is 
investigated for two positron emission tomography (PET) tracers: 
11
Carbon-
Methionine (CMET), and 3’-deoxy-3’-18Fluorine-fluorothymidine (FLT). These two 
PET tracers, as well as gadolinium enhanced T1 weighted MRI (Gd-MRI) were then 
assessed for their utility in survival prediction based on the volume of brain tissue 
demonstrating elevated uptake/enhancement in each modality. This research has two 
main aims with regards to brain imaging in glioma: to identify an ideal post-injection 
waiting period for glioma PET imaging with CMET, and with FLT (addressed in 
Chapter 2); and to quantify the degree to which CMET, FLT, and Gd-MRI can be 
used to predict survival in a cohort of post-treatment glioma patients (addressed in 
Chapter 3). 
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The prevalence of AD, and the costs associated with it, has risen inextricably with 
life expectancy in the Western world. The medial temporal lobe of the cerebrum is a 
brain region that shows significant early physical atrophy in AD (Jack et al. 1997). 
Atrophy of the hippocampus in particular is known to be an early indicator of AD 
(Morra et al. 2009). Such severe atrophy can result in a decrease in localised glucose 
metabolic rate (MRglc). The small size of the atrophied hippocampus can result in 
the quantification of a reduction in MRglc to be hampered by partial volume effects. 
Attempts to observe the expected reduction in MRglc in the hippocampus using 
functional brain imaging have often failed in studies that have used voxel based 
analysis (VBA) methods of image spatial normalisation to register images to a 
standard space; this was likely due to registration errors causing inconsistencies in 
hippocampal location between subjects (Mosconi et al. 2005). An optimised 
volumetric mask based on manually outlined subject hippocampal regions has shown 
utility in detecting reductions in localised MRglc in AD and mildly cognitively 
impaired (MCI) brains (Mosconi et al. 2005). In this thesis, a manually outlined 
mask is compared with one that was based on automatically defined hippocampal 
volumes by the program FSL (Smith et al. 2004) with regards to their utility in 
reduced hippocampal MRglc detection in groups of mildly cognitively impaired 
(MCI) and AD brains. The FSL subject hippocampal volume based mask was then 
further tested for its potential utility in the diagnosis of an individual, both when a 
subject MRI is present to guide spatial normalisation, and when it is absent. The aims 
of this research in AD brain image analysis are: to quantify the efficacy of two 
different hippocampal masking techniques in detecting group level differences in 
MRglc between cohorts of Healthy Control (HC), MCI, and AD brains using deoxy-
2-[
18
F]fluoroglucose (FDG)-PET (addressed in Chapter 4); and to assess the potential 
clinical utility of an automated hippocampal masking algorithm in MCI and AD 
diagnosis (addressed in Chapter 5). 
 
This chapter introduces important background concepts for the thesis, and reviews 
relevant literature in the field. 
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1.2 Brain Anatomy and Function 
 
The average adult human brain weighs approximately 1400 grams and has a volume 
of 1200 cm
3
 (Carpenter and Sutin 1983). It has approximate symmetry along the 
central sagittal plane, and as such can be divided into left and right hemispheres. The 
total brain volume can be divided into three regions: the brainstem, the cerebellum, 
and the cerebrum. These three regions are shown in Figure 1. 
 
 
Figure 1, The cerebellum, cerebrum and brainstem (Gray and Lewis 1918, p 766) 
 
The bone structure of the skull, as well as three distinct membranes between the 
brain and the skull, protect the brain from impact trauma. The extremely tough, 
outermost membrane is the dura mater. Inside this is the intermediate membrane, the 
arachnoid. The innermost membrane is the pia mater, which is extremely delicate 
and adheres very closely to the brain’s surface. The brain is suspended in a colourless 
liquid called cerebrospinal fluid (CSF), situated inside the arachnoid membrane. CSF 
also flows down through the spinal column, and acts as an impact-dampening 
mechanism for the brain. CSF forms an important component of the system of 
barriers that allow for “… maintenance of the cerebral environment and protection of 
the brain from the systemic circulation” (Deisenhammer et al. 2015, p 18). 
 
 
Brainstem 
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1.2.1 Vascularisation, the Blood-Brain Barrier, and Energy 
 Metabolism 
 
1.2.1.1 Vascularisation 
 
The human brain receives an extremely large proportion of cardiac and metabolic 
output relative to its size. Roughly 15% of blood flow is directed to the brain, and 
around 20% of the body’s resting metabolic rate is required to maintain brain 
function (Siegel and Agranoff 1999). Despite the fact that normal brain tissue 
accounts for about 2% of the body’s mass, it has the highest rate of glucose 
metabolism of any healthy tissue in the body (Gulyas and Halldin 2012). Blood is 
delivered to the cerebrum via the internal carotid arteries, and to the cerebellum and 
brain stem via the vertebral arteries, both of which are bilateral (Cipolla 2009), 
Figure 2 shows the location of these arteries on the right hand side of the neck. 
 
 
Figure 2, The locations of the right Internal Carotid and Vertebral Arteries (Gray and Lewis 1918, 
p 567). 
 
1.2.1.2 The Blood-Brain Barrier 
 
The blood-brain barrier (BBB) is a term that describes the biological system 
controlling the flow of material between the brain and the rest of the body. This 
barrier is vital for optimal cerebral performance, as it allows the brain to maintain the 
Internal Carotid Artery 
Internal Vertebral Artery 
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correct concentration of ions needed for proper function, and protects it from blood-
borne pathogens (Saunders et al. 2008). The BBB is “… a fundamental physical 
barrier at the level of intercellular junctions between cells” (Saunders et al. 2008, p 
279), and is present across a large number of blood vessels in contact with the brain. 
Part of the overall BBB system is the blood-cerebrospinal fluid barrier (BCSFB), 
located in the choroid plexus, found in each of the brain’s ventricles.  Figure 3 
depicts the location of blood vessels on the inferior surface on the brain, displaying 
the extent of vascularisation that is present. Figure 4 is an illustration of the location 
of the ventricles of the brain. 
 
 
Figure 3, The network of blood vessels on the inferior brain surface (Gray and Lewis 1918, p 572). 
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Figure 4, The location of the ventricles of the brain (Gray and Lewis 1918, p 829). 
 
Figure 5 shows the location of the choroid plexus in a lateral ventricle. The choroid 
plexus “… regulates the exchange of fluid and solutes between blood and CSF in 
part by acting as a passive, paracellular barrier to solutes” (Zheng and Chodobski 
2005, p 26). As well as forming a vital component of the overall BBB, the choroid 
plexus continually produces ‘fresh’ CSF, controls the flow of CSF between the 
ventricles and pia mater-arachnoid cavity, and fulfils a similar role within the brain 
as the kidneys do for the overall blood stream, that is, the filtration and removal of 
waste products and metabolites. 
 
Fourth Ventricle Cerebral Aqueduct 
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Figure 5, A coronal cross-section of the inferior horn of the lateral ventricle (Gray and Lewis 1918, 
p 841). 
 
The BBB is highly effective at allowing the brain to operate in a healthy manner, but 
can prove a significant obstacle in drug delivery and imaging. In-vivo imaging agents 
are often limited to molecules that can freely traverse the BBB. However, pathology 
that includes disruption of the BBB can be highlighted by use of an imaging agent 
that is only able to enter the brain in specific regions of disruption. Clinically, 
disruption of the BBB can be shown using Gd-MRI, as the gadolinium will pool in, 
and therefore highlight, areas of BBB disruption. 
 
1.2.1.3 Energy Metabolism 
 
The majority of cellular work within the body is powered by Adenosine 
Triphosphate (ATP), which is produced by the oxidation of glucose during cellular 
respiration. Some cells, such as those found in muscle, are capable of storing 
significant amounts of glycogen (enough to power them for up to a day without 
replenishment from food). Glycogen can then be converted to glucose via hydrolysis. 
These cells can also store oxygen through the usage of myoglobin (Campbell and 
Reece 2002). The brain stores some glycogen, but in very low concentrations 
compared to the aforementioned tissues, and does not have intracellular oxygen 
storage capacity. The brain therefore requires a constant supply of both glucose and 
Lateral Ventricle 
Choroid Plexus 
Pia Mater 
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oxygen for survival, which is delivered through the vascular system. Oxygen is able 
to diffuse across cell membranes and so is able to freely traverse the BBB in 
accordance with the concentration gradient. Specific transporters exist within the 
endothelial cells of the BBB for the uptake of glucose, so that it may be absorbed 
from the brain’s arterial blood supply through facilitated diffusion (Siegel and 
Agranoff 1999).  
 
Since glucose is absorbed from the blood as required, the total cerebral uptake of 
glucose is proportional to the amount of neuronal activity taking place in the brain at 
a given moment in time. This principle is also applicable to smaller volumes within 
the brain itself; that is, the localised instantaneous rate of glucose uptake and/or 
blood perfusion in a given volume is proportional to the amount of neuronal activity 
within that volume. Therefore, imaging the rate of glucose metabolism within the 
brain serves as a surrogate means to visualise neuronal activity. 
 
1.2.2 The Cerebrum 
 
The outermost layer of the cerebrum is called the cerebral cortex, and is divided 
anatomically into four lobes: frontal, parietal, temporal and occipital. The lobes of 
the cerebral cortex are shown in Figure 6. 
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Figure 6, The four lobes of the cerebral cortex (Gray and Lewis 1918, p 821). 
 
Different regions of the cerebral cortex perform different neurological functions. As 
the brain develops during childhood, the hemispheres specialise in a distinct manner. 
The left hemisphere specialises towards “… language, math, logic operations, and 
the processing of serial sequences of information” (Campbell and Reece 2002, p 
1049), whereas the right hemisphere is “… stronger at pattern recognition, face 
recognition, spatial relations, nonverbal ideation, emotional processing in general, 
and parallel processing of many kinds of information” (Campbell and Reece 2002, p 
1049). As can be seen in the coronal slice depicted in Figure 7, the cerebral cortex is 
arranged in a pattern of ridges (gyri) and furrows (sulci). Major gyri and sulci form 
the borders of the lobes of the cerebrum. Many of the major gyri and sulci and some 
of the functional areas of the cerebrum are highlighted in Figure 8. 
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Figure 7, A coronal slice through the cerebrum showing the location and folds of the cerebral 
cortex (Gray and Lewis 1918, p 810). 
 
 
Figure 8, Some of the major gyri and sulci, and functional areas on the lateral surface of the 
cerebrum. Red denotes the motor areas, general sensation areas in blue, auditory areas in green 
and visual areas in yellow. Modified from Gray and Lewis (1918), p 821. 
 
Cerebral Cortex 
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Located inside the cerebrum is the sub-cortex, which contains multitudinal individual 
subcortical structures. Some of these are highlighted in Figure 9. 
 
 
Figure 9, A coronal slice of the cerebrum showing several subcortical structures (Gray and Lewis 
1918, p 809). 
 
Of particular importance to AD is the hippocampus, a bilateral structure situated 
within the temporal lobe of each hemisphere. The inferior horn of the lateral 
ventricle lies around the edge of the hippocampus, and is bordered by the lateral 
ventricle on the superior and lateral sides (refer Figure 10). At the medial edge of the 
hippocampus is the dentate gyrus, and the inferior borders the subiculum and 
parahippocampal gyrus (Gardner et al. 1975). The location of the hippocampus from 
a sagittal viewpoint is shown in Figure 11. 
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Figure 10, An axial cutaway through the cerebrum showing the location of the hippocampus and 
pes hippocampus (Gray and Lewis 1918, p 833). 
 
 
Figure 11, A cutaway sagittal view showing the location of the hippocampus (Gray and Lewis 1918, 
p 832).  
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1.2.3 The Cerebellum and the Brainstem 
 
The cerebellum lies inferior to the occipital and posterior portion of the temporal 
lobes of the cerebrum. The cerebellum is not as ‘advanced’ in an evolutionary sense 
as the cerebrum, and does not play a role in sensory perception or the formation of 
thoughts or memories. Its functions include the coordination of muscle movement 
and balance, which is achieves with the aid of collateral input from the sensory 
system (Waxman 2013).  
 
Attaching the brain to the spinal cord is the brainstem. It lies inferior to the cerebrum 
and to the anterior of the cerebellum. Including such structures as the pons and 
medulla, the brainstem is responsible for the regulation of several essential 
automated functions, such as breathing, heartbeat, and blood pressure (Waxman 
2013). The pons can be of particular interest in AD research. One of the symptoms of 
AD is a reduced metabolic rate across several key areas of the cerebrum (McKhann 
et al. (2011); Minoshima et al. (1997)). The pons, however, has been shown to 
maintain pre-AD levels of glucose metabolism throughout the duration of the disease 
(Minoshima et al. 1995). Consequently, the localised metabolic rate seen in parts of 
the cerebrum of AD patients can be normalised to the metabolic rate in the pons in 
order to provide an estimate of degree of localised cerebral metabolic degradation. 
The brainstem and cerebellum can be seen in sagittal view in Figure 12. 
 
 
Figure 12, The brainstem and the cerebellum, shown in sagittal view (Gray and Lewis 1918, p 798).  
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1.3 Glioma 
 
Glioma is the term given to a range of tumours of the central nervous system (CNS) 
that originate from glial cells. Gliomas are the most common tumour of the brain and 
are responsible for 49% of all primary brain tumours and approximately 2% of new 
cancer cases in the USA; life expectancy following a glioma diagnosis is poor, most 
patients die within 12 months (Hayat 2011). The treatment method of surgical 
debulking, followed by chemoradiotherapy, can increase median life expectancy to 
over a year, and the two year survival rate from 10% to 26% (Stupp et al. 2005). 
 
1.3.1 Symptoms and Diagnosis 
 
Symptoms of glioma can vary depending on their location in the CNS, type and 
severity. Symptoms can include nausea and/or vomiting, headaches, trouble 
balancing or asymmetrical physical weakness, memory and speech difficulty, 
fainting, seizures, incontinence, back and neck pain, as well as depression, irritability 
and other personality changes. Mental symptoms of glioma can also affect the 
patients’ decision-making ability and judgement process, and cause further delays in 
the formation of a proper diagnosis due to sufferers’ lack of willingness to see a 
physician. Symptoms may develop slowly and are often ignored or mistaken for 
other ailments (Salander et al. 1999). 
 
Once symptoms have been assessed and glioma is considered a possibility, a 
preliminary diagnosis can be made using radiologic imaging. Gd-MRI is effective in 
showing increased intensity in a tumour region, provided there is disruption of the 
BBB. The best procedure is to perform two MRIs, one with and one without 
gadolinium enhancement (Behin et al. 2003). If MRI is not available, CT can be used 
to assess a lesion quickly; however, it is much less sensitive than MRI. Due to the 
lack of specificity of imaging methods, histological assessment of a biopsy sample is 
also required for a definitive diagnosis (Behin et al. 2003). Once a diagnosis is made, 
the tumour is staged and graded from ‘I’ to ‘IV’, where IV is the highest grade given, 
corresponding to the worst prognosis. 
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1.3.2 Pathology 
 
Several different types of gliomas exist, variations are dependent on the type of glial 
cell from which they originated. The vast majority of glioma patients included in this 
research were adults with glioblastoma multiforme. The specific pathology of this 
malignancy is discussed below. 
 
More than 50% of malignant gliomas are glioblastoma multiforme, making it the 
most common primary brain tumour among adults. It is a rapid-growing malignancy 
that exhibits resistance to both radio- and chemotherapy; however, even with 
aggressive management, recurrence is almost always inevitable. Glioblastomas “… 
consist mainly of undifferentiated anaplastic cells of astrocytic origin, which exhibit 
marked nuclear pleomorphism, necrosis and vascular endothelial proliferation” 
(Hayat 2011, p 4). Glioblastoma occurs mostly in the cerebrum of adults, and the 
tumour cells are usually arranged radially with respect to the necrotic region. 
Surgical resection, although often performed, is rarely curative due to the highly 
invasive and irregular growth of this type of tumour (Wirth et al. 2011).  
 
1.3.3 Treatment 
 
Treatment options for Glioma patients can vary depending on the location and mass 
of the tumour, as well as the age of the patient. Surgical removal or debulking (if 
possible) followed by chemoradiotherapy, is currently considered the standard 
strategy for treatment. Increased median life expectancy has been reported by using 
fractionated focal irradiation in daily fractions of two Gy given five days per week 
for six weeks, along with continuous temozolomide (75 mg per square metre of 
body-surface area per day), followed by six cycles of temozolomide (150-200 mg 
square metre of body-surface area per day for five days during each 28 day cycle) 
(Stupp et al. 2005). 
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1.3.4 Imaging 
 
As stated in Section 1.3.1, radiologic imaging is used as part of the initial diagnostic 
procedure for glioma. Once a positive diagnosis is made, further imaging is 
performed to aid in surgical guiding and to monitor patient recovery and post-surgery 
condition. CT and MRI are both useful for the formation of an initial diagnosis. MRI 
in glioma imaging is usually enhanced with the intravenously-administered MRI 
contrast agent, gadolinium diethylenetriaminepentaacetate (Gd-DTPA). Once 
administered, Gd-DTPA is distributed throughout the vascular system. If there is a 
breakdown of the BBB, the extravascular leakage leads to pooling of Gd-DTPA in 
the affected region, increasing its intensity on MRI (Carr et al. 1984).  Both CT and 
MRI are of limited use for monitoring treatment outcomes as they “… cannot 
reliably differentiate viable tumour tissue from treatment-induced non neoplastic 
changes, such as oedema, postoperative changes or radiation necrosis” (Vander 
Borght et al. 2010, p 10). Several different nuclear medicine radioisotopes have been 
investigated for use in glioma imaging. FDG is the most widely used PET tracer, and 
has been used extensively in glioma studies. The two tracers used in this research are 
11
Carbon-Methionine (CMET) and 3’-deoxy-3’-18Fluorine-fluorothymidine (FLT). 
 
1.3.4.1 2-Deoxy-2-[18F]Fluoroglucose 
 
Neoplasmic cancer cells are known to metabolise glucose at a rate that is much 
higher than that of most healthy tissue, a phenomenon known as the Warburg Effect 
(Warburg 1956). FDG is a glucose analogue that is used to image the relative 
localised cellular metabolic rate (MRglc). As a result, FDG imaging is able to take 
advantage of the Warburg Effect, and is extensively used to stage and re-stage 
various pathologically proven cancers throughout the body, monitor treatment 
progression, and identify distant metastases (Kelloff et al. 2005). 
 
Imaging cancers within the brain with FDG can be more problematic than other parts 
of the body, as healthy brain tissue also has a very high metabolic rate (see Section 
1.2.1). It is therefore more difficult to see a distinction between normal tissue uptake 
and tumour uptake. FDG uptake is more likely to be noticeably elevated in high 
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grade (III and IV) than in low grade (I and II) glioma, with high hazard ratios (4.6 
and 11 for right and left hemisphere tumours respectively) found for patients 
showing high FDG tumour uptake (Padma et al. 2003). However, up to 14% of high 
grade gliomas have been shown to exhibit lower FDG uptake than the surrounding 
tissue (Padma et al. 2003). FDG has shown limited utility in distinguishing tumour 
recurrence from radiation necrosis. Using contralateral white matter uptake as a 
normalisation standard, radiation necrosis has been successfully distinguished from 
tumour progression with a sensitivity of 86 ± 14 %, specificity of 22 ± 6%, positive 
predictive value of 73 ± 20%,  and negative predictive value of 50 ± 49%. These 
results were shown in a study by Ricci and colleagues (1998) where histopathologic 
confirmation of tumour progression was available. 
 
1.3.4.2 11Carbon-Methionine 
 
Methionine is one of 20 standard amino acids used in the production of proteins and 
generation of metabolic energy. It is one of 10 essential amino acids, meaning that it 
cannot be synthesised inside the human body and must be ingested directly. 
Methionine is required by the body for the processes of protein synthesis and the 
methylation of DNA, guanidoacetate, norepinephrine, and RNA (Fromm and 
Hargrove 2012). The BBB shows selective permeability to amino acids; methionine 
is one of a group of large neutral amino acids that are able to traverse the BBB via 
the L-Type amino acid transporter system (Betz and Goldstein (1978); Okubo et al. 
(2010); Oldendorf (1971)). Capillaries inside glioma tissue have been shown to have 
up-regulated amino acid transporter expression compared with healthy brain tissue 
(Miyagawa et al. 1998); this factor, combined with increased micro vessel density, 
leads to elevated CMET uptake (Kracht et al. 2003). 
 
CMET-PET has been used as a means of imaging the rate of amino acid metabolism 
in glioma (Okubo et al. 2010). It has been found that CMET can provide superior 
tumour-healthy tissue contrast when compared with FDG (Bergstrom et al. 1983). 
Elevated uptake of CMET is also present in low grade tumours (Herholz et al. 1998). 
CMET has shown high utility in tumour detection and delineation, as well as 
differentiation between benign and malignant lesions (Kawai et al. 2011).  
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1.3.4.3 3’-deoxy-3’-18Fluorine-Fluorothymidine 
 
The nucleoside thymidine is an essential component in the production and replication 
of DNA and RNA (Fromm and Hargrove 2012). FLT is phosphorylated within cells 
by thymidine kinase-1 (TK1) (Rasey et al. 2002), the increased concentration of 
which is an effective proxy for neoplasmic cellular proliferation. As stated by 
Munch-Peterson and colleagues (1995, p 70) “TK1 activity is known to fluctuate 
with cellular DNA synthesis, the activity being high in proliferating and malignant 
cells and low or absent in quiescent cells”.  
 
FLT cannot cross an intact BBB, resulting in very low uptake in healthy brain tissue 
(Chen et al. 2005). High FLT uptake in brain imaging only occurs when there is 
disruption of the BBB, which is often seen in glioma. Any measure that does not take 
into account transport methods (such as the Standardised Uptake Value (SUV)) can 
be misleading in FLT imaging, as it is likely that most FLT uptake is due to transport 
through the broken down BBB, and not due to trapping of FLT after phosphorylation 
by TK1 (Jacobs et al. 2005). This can result in high uptake in regions of BBB 
breakdown that are not highly proliferating, and low uptake in instances of glioma 
that involve minimal BBB disruption, which is possible even in highly proliferative 
tumours (Muzi et al. 2006).  
 
In spite of the potentially confounding factors surrounding the nature of its uptake in 
the brain, FLT has shown promise as a diagnostic tool for the staging and evaluation 
of glioma. FLT may have greatest utility when used in conjunction with other 
modalities such as Gd-MRI and CMET when evaluating treatment effects and 
tumour recurrence (Jacobs et al. 2005). 
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1.4 Alzheimer’s Disease and Mild Cognitive Impairment 
 
As life expectancy increases, so too does the significance of diseases that primarily 
affect the elderly, such as dementia. It is estimated that there were over 266,000 
Australians with dementia in 2011; that figure is expected to rise to over 942,000 by 
2050 (Deloitte Access Economics 2011). AD is the most common form of dementia, 
accounting for 50-70% of all diagnosed dementia cases. The cost associated with 
dementia in Australia in 2009-10 has been estimated at $4.9bn (Australian Institute 
of Health and Welfare 2012). 
 
Early clinical diagnosis of AD can be extremely difficult due to the gradual onset of 
symptoms and variation of symptomatic experience between individuals. The use of 
in-vivo cerebrospinal fluid (CSF) assays and brain imaging have led to identification 
of AD-related pathophysiological processes occurring as early as decades before the 
onset of clinically evident symptoms (Sperling et al. 2011). There are three main 
phases in the development of AD. The first stage is a pre-clinical, asymptomatic 
phase during which AD pathophysiology may start to present. The second stage is 
known as Mild Cognitive Impairment (MCI) (Albert et al. 2011). During this stage, 
the onset of some clinical signs of AD are observed, although not enough to cause 
significant impairment. Stage three is clinically diagnosable AD. There is a fluid 
continuum of progression between normal cognitive health and AD, and as such it 
can be difficult to establish a definitive diagnostic timeline of disease progression. 
Furthermore, MCI syndrome can occur independent of AD, with other causes such as 
brain trauma and other medical reasons such as Parkinson’s disease being possible 
causes (Albert et al. 2011). 
 
There is currently no cure for AD, and the only treatments available involve methods 
to lessen the severity of symptoms, rather than treat the disease itself. On average, 
life expectancy following diagnosis is seven years; less than three per cent of patients 
live for fourteen years after diagnosis (Shelton 2012). 
 
 
 
 20 
 
1.4.1 Symptoms 
 
The earliest symptoms of AD are often mistaken for cognitive decline as a normal 
part of aging, or as symptoms of stress or depression. The most commonly seen 
initial symptom is loss of episodic memory (the ability to form and keep new 
memories) (Shelton 2012). AD can remain undiagnosed for years, and the timing of 
the onset of symptoms and progression of the disease can vary greatly between 
patients.  
 
Observable symptoms of MCI are similar to AD, but less severe. MCI symptoms 
include a decline in one or more areas of cognition that has either been noticed by a 
patient themselves or by a carer/family member, or has become evident in 
longitudinal cognitive testing. Symptomatic cognitive decline due to MCI should not 
be so severe as to significantly obstruct the patient’s social or occupational life; such 
catastrophic decline is part of fully developed AD. In MCI due to AD, episodic 
memory is usually the most heavily affected area of cognition (Albert et al. 2011).  In 
AD, the initial loss of memory and onset of confusion is followed by a range of other 
symptoms which varies between patients. These symptoms can include increased 
irritability, mood swings and aggression, loss of long-term memory, language 
breakdown, and gradual withdrawal of the patient as their cognitive decline 
progresses. Eventually the patient’s bodily functions start to fail. Death results, 
although the specific cause can be a coexisting chronic condition or complications 
from other diseases such as pneumonia.  
 
1.4.2 Diagnosis 
 
Ante-mortem AD diagnosis cannot yet be undertaken with 100% certainty (Lu and 
Bludau 2011). The gold standard for AD diagnosis is obtained through post-mortem 
histopathological examination of brain tissue. Neuropathologic change is assessed 
according to three parameters: Amyloid Beta (Aβ) plaque score, neuritic plaque 
score, and neurofibrillary tangle stage (Hyman et al. 2012).  
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The first step in an attempt to make an ante-mortem MCI or AD diagnosis is clinical 
cognitive assessment. Standard criteria exist for clinical diagnosis of MCI due to AD 
(Albert et al. 2011). Cognitive assessment is typically performed by having the 
patient complete a series of assessments that test their cognitive abilities across a 
range of disciplines. The first such test proposed was the Mini Mental State 
Examination (MMSE) (Folstein et al. 1975). An improved, modernised version of 
the MMSE is now available, called the Standardized Mini Mental State Examination 
(Molloy and Standish 1997), which can be used as part of a clinical AD assessment. 
Other clinical cognitive assessment tools include the Clinical Dementia Rating 
(CDR) (Morris 1993) and the Global Deterioration Scale (GDS) (Reisberg et al. 
1982). Assessment ideally occurs over a series of visits to enable some tracking of 
cognitive decline, although it is possible to make a diagnosis in a single visit if an 
informant is available to provide information on the patient’s cognitive history. 
Clinically, MCI is defined as decline in one or more areas of cognition that result in 
the patient scoring significantly lower (1 to 1.5 standard deviations) in a cognitive 
assessment than would typically be expected for a patient of their age and level of 
education (Albert et al. 2011).  
 
Clinical standards also exist for a diagnosis of AD through cognitive assessment 
(McKhann et al. 2011). The most important part of an AD diagnosis (as with an MCI 
due to AD diagnosis) is to attempt to establish episodic memory impairment. 
Generally, a patient is also required to show a decline in at least two other cognitive 
areas (aphasia, agnosia, apraxia, or disturbance in executive function) for a positive 
diagnosis of AD (McKhann et al. 2011).  
 
In-vivo structural brain imaging is used clinically (if available) to help rule out other 
causes for the patient’s symptoms such as stroke, subdural haemorrhage, or a tumour. 
The use of structural and functional brain imaging to detect AD pathology has been 
the subject of a large (and growing) field of research for several decades, and is 
further discussed in Section 1.4.5. 
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1.4.3 Pathology 
 
There are three main pathological characteristics of AD; these are the accumulation 
of amyloid plaques, the formation of neurofibrillary tangles within the cellular 
matrix, and destruction of synapses and neurons (Kadir et al. 2012). Additionally, 
significant loss of white matter and reduction of cholinergic neurons has been 
observed in AD patients (Lombardo and Maskos 2015). An associated reduction in 
nicotine binding sites can be seen in-vivo by uitilising the PET tracers 
11
C-nicotine 
and 
18
F-A85380 (Herholz et al. 2007). 
 
The presence of βA (also called senile) plaques in the brain has long been associated 
with AD, both as a component of intracellular neurofibrillary tangles,  and as 
depositions in the extracellular vascular system (Hyman et al. 1989). The presence of 
βA plaques is considered to be a crucial element in the formation of a post-mortem 
AD diagnosis (The National Institute on Aging 1997). 
 
Neurofibrillary tangles were one of the earliest pathological observations made in the 
study of AD, and are also considered a requirement for a positive post-mortem AD 
diagnosis (Perl 2010). There are several different proteins that comprise AD 
neurofibrillary tangles, including ubiquitin (Perry et al. 1987), cholinesterases 
(Mesulam and Asuncion Moran 1987), βA (Hyman et al. 1989), and tau (Lee et al. 
1991). Tangles are observed in several different diseases (Wisniewski et al. 1979), 
which is why it is important that βA plaques are also observed to make a definitive 
diagnosis. Neurofibrillary tangles and amyloid plaques within the brain can only be 
directly observed in-vitro during a histological examination. Indirect observation of 
βA plaques in-vivo is possible using several PET tracers, including Pittsburgh 
compound B (PiB) and 2-(1-{6-[(2-[fluorine-18]fluoroethyl)(methyl)amino]-2-
naphthyl}-ethylidene)malononitrile (FDDNP) (Vlassenko et al. 2012). Numerous 
18
F 
PET tracers have been utilised to observe tau protein aggregates within 
neurofibrillary tangles, including THK523, T807, and T808 (Chien et al. 2013). 
 
Neuronal and synaptic loss from AD can be seen in vivo using volumetric MRI. 
Sufferers of advanced AD will usually exhibit severe cerebral atrophy, which is 
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particularly evident in the widening of the lateral ventricles (Apostolova et al. 2012) 
and reduction of overall brain volume (Fox and Freeborough 1997). Accelerated 
atrophy of the medial temporal lobe is one of the well-established hallmarks of AD 
(Jack et al. 1997). In particular, increased atrophy of the hippocampus due to AD has 
been the subject of many studies (Morra et al. (2009); Ridha et al. (2006); Schott et 
al. (2005); Villain et al. (2008)). Severe atrophy of the hippocampus is considered to 
be one of the few reliable macroscopic indications of AD. A lack of significant 
hippocampal atrophy in a post-mortem brain examination is considered to be 
strongly suggestive that other causes of dementia need to be sought (Perl 2010). 
 
1.4.4 Treatment 
 
Current FDA-approved drugs for the treatment of AD include several different 
cholinesterase inhibitors and Memantine, which is an N-Methyl-D-asparate (NMDA) 
receptor antagonist. These drugs can provide temporary symptomatic relief, but have 
little to no effect on the progression of the disease. Research aimed at producing 
pharmacological treatments for AD is primarily focussed on development of ‘disease 
modifying drugs’ that may actually slow, halt, or even reverse the progression of the 
disease itself. An early start to treatment is likely to be vital to maximise the efficacy 
of such drugs (Salomone et al. 2012). 
 
Non-pharmacological treatments for AD include cognitive training and stimulation, 
reminiscence, use of music, transcutaneous electrical stimulation, use of light, 
massage and touch, and physical exercise. Also beneficial is education for patients 
and carers, including strategies on how to deal with AD symptoms and episodes. 
Various combinations of these therapies have been shown to temporarily improve 
cognitive function, delay the need for institutionalisation, and improve the mood and 
behaviour of the patient (Olazaran et al. 2010). 
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1.4.5 Imaging 
 
In-vivo brain imaging has been used extensively for AD research. The two 
modalities most relevant in this research are volumetric structural MRI and FDG-
PET. 
 
Volumetric structural MRI has been used to find quantitative differences between 
AD and HC brains in-vivo. Factors such as increased overall brain atrophy (Schott et 
al. 2005), enlargement of the lateral ventricles (Apostolova et al. 2012), and severe 
hippocampal atrophy (Ringman et al. 2010) are observed in AD brains.   
 
Although there are many isotopes that have been developed for PET imaging, by far 
the most commonly used is FDG. As noted in Section 1.2.1, the brain requires a 
constant vascular supply of glucose. FDG in brain imaging is used as a means to 
indirectly observe MRglc. FDG “… is actively transported across the blood-brain 
barrier (BBB) into the cells where it is phosphorylated by hexokinase, then 
effectively ‘trapped’ ” (Vander Borght et al. 2010, p 9). PET brain imaging with 
FDG has been used to detect depressed cellular metabolism in the temporo-parietal 
cortex (and specifically in the hippocampus) as a result of AD (McKhann et al. 
2011). FDG-PET has also been used to detect the depression of cerebral metabolism 
in the posterior cingulate cortex of AD patients that are yet to develop clinically 
observable symptoms (Minoshima et al. 1997). In clinical trials, FDG-PET has been 
shown to be beneficial for diagnostic sensitivity when used in conjunction with other 
diagnostic methods (Silverman and Small 2002). 
 
1.5 Brain Image Analysis 
 
As high resolution structural brain images and a greater variety of functional imaging 
techniques become more widely available, the automated analysis of brain images 
continues to develop as a crucial tool for both research and clinical applications. A 
method that allows for voxel-by-voxel comparison of brain images to be made is to 
transform them to the same co-ordinate space. This is achieved through 
implementation of spatial transformations. Intra-subject image alignment can be 
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achieved using a rigid body transform, as no change to the overall shape or size of 
the images is desired. Inter-subject alignment is generally achieved utilising a two-
stage process. Computationally simple linear transforms can be used to bring the 
images into approximate alignment, this serves as a starting point for the next stage. 
Nonlinear transforms can then be implemented to provide a much closer anatomical 
alignment, which is crucial for the study of small tissue volumes such as the 
hippocampus. 
 
1.5.1 Linear Transforms 
 
A rigid body transform involves up to two different types of transformation: 
translation and rotation. In a three dimensional volume, this provides up to six 
degrees of freedom. A rigid body transformation in the context of brain imaging is 
most useful for intra-subject registration, as no overall changes to brain shape or size 
are required to achieve a precise registration between multiple images of the same 
brain, provided a negligible amount of time has passed between images. Rigid body 
transformations are a subset of affine transformations, which involve up to 12 
degrees of freedom. Affine transformations, as well as translations and rotations, can 
include zooms and shears. 
 
An automated algorithm that attempts to find the optimal set of transformation 
parameters between two volumes will usually do so through an iterative process that 
has the goal of minimising a cost function. A popular cost function to use for within-
modality registration is the sum of squared differences in voxel numbers between the 
two images. It is the minimisation of this parameter that should give the best 
registration (Friston 2007). However, the sum of squared differences is not of great 
use when it comes to inter-modality registrations, since there is not necessarily any 
correlation between anatomy and voxel number between imaging modalities. This is 
particularly relevant when attempting to create a functional-structural registration. 
 
Inter-modality registration requires a more sophisticated approach. Early techniques 
for inter-modality registration involved manually marking corresponding features on 
each image that could then be aligned with one another (Pelizzari et al. 1989). This 
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approach can provide a high level of accuracy; however, it is cumbersome 
(particularly for batch processing of many images) and subject to operator error and 
inter-operator variability. Since then, techniques have been developed that can be 
used for fully automated inter-modality registration such as Mutual Information 
(Viola and Wells Iii 1997) and the Correlation Ratio  (Roche et al. 1998), both of 
which rely on the use of joint probability density functions derived from a series of 
two dimensional intensity histograms to maximise the degree of likelihood between 
two image volumes. 
 
1.5.2 Nonlinear Transformations 
 
Natural variations in overall size and shape, as well as the effects of aging and 
pathology, can create large discrepancies between brains, which may render linear 
transforms useless for all but the most approximate alignment. In order to create a 
close registration that enables the overlay and comparison of small structures within 
the subcortex, higher order nonlinear transforms are required. Nonlinear transforms 
are usually applied after a linear transform has been used to gain an approximate 
alignment. Use of a linear transform to provide a starting estimate is very important, 
as nonlinear transforms for brain alignment usually conduct deformations over a 
small spatial scale (Andersson et al. 2007). 
 
As is the case with linear transforms, nonlinear transforms generally operate by 
minimising a cost function. The assumption is that values of a set of parameters that 
minimise the cost function will correspond to the ‘correct’ alignment of the two 
images. Nonlinear warping is much more complicated and computationally intensive 
than the linear equivalent, involving potentially millions of degrees of freedom.  
 
There are two general types of nonlinear transforms, label-based and intensity-based 
(Friston 2007). Label-based techniques work by identifying points or surfaces within 
the brain material that are common between brains. These elements are then aligned 
with each other, before fitting a series of splines and minimising ‘bending’ 
(Bookstein 1989) or ‘membrane’ energy (Andersson et al. 2007),  or using a fluid 
model (Thompson and Toga 1996) to interpolate between the labelled points. The 
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use of this technique has limited application in brain registration. There can be 
significant variations in physical characteristics between healthy brains, such as 
disparities in the number of sulci. Changes resulting from aging and pathology can 
further reduce the number of physical features that are common between two brains 
(Andersson et al. 2007). 
 
Intensity-based techniques operate by treating brains as unlabelled, continuous 
volumes and applying warping methods to optimise a cost function used to quantify 
the differences between the images. Nonlinear warping in the software package FSL 
(Smith et al. 2004)  for intra-modality alignment uses a weighted combination of 
both label-based and intensity based-techniques (Andersson et al. 2007). 
 
1.5.3 Segmentation 
 
The resolution that can be achieved in cerebral imaging allows for clear definition of 
sub-structures within the brain. Segmentation of cerebral sub-structures allows for 
quantitative analysis of sub-structure volume in a structural image, and 
uptake/activity quantification within a substructure on functional images that are in 
precise alignment with a segmented structural image. This segmentation can be 
achieved manually through the marking of a structure boundary over its volume; this 
process is tedious and cumbersome. It requires significant expertise in cerebral 
anatomy and imaging characteristics, and is vulnerable to inter-operator variability 
and human error. Automated brain image segmentation provides a faster, 
mathematically consistent replacement to the manual option. 
 
The automated segmentation of brain tissue can be performed through several 
different methods. Segmentation can be performed based on generalised tissue 
classification (grey matter, white matter, CSF) on MRI  by creating an intensity-
based separation model (Friston 2007). Some structures and tissue types are 
indistinguishable from one another based solely on signal intensity; models that 
incorporate segmentation of the structures of the subcortex do so through utilization 
of manually labelled data sets to assist in estimation of spatial location of the 
included structures. Since there is often little change in MRI signal intensity between 
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structures of the subcortex, methodologies that include their segmentation must also 
incorporate some means of boundary identification. This can be achieved by 
including the computation of tissue class probability statistics on a voxel-by-voxel 
basis, and estimating boundaries based on a statistical threshold (Fischl et al. 2002), 
and through use of deformable virtual surface meshes for each structure (Patenaude 
et al. 2011). 
 
1.5.4 The Standardised Uptake Value, SUVMAX and SUVPEAK 
 
The intensity of each voxel in a correctly reconstructed nuclear medicine image is 
directly proportional to the amount of radioactivity detected within the volume. 
While this can be useful in a clinical setting (e.g. qualitative visual comparisons of 
regional FDG uptake between brain structures for clinical assessment of AD), the 
ideal scenario is one in which regional volumetric activity concentration can be 
quantified. Such quantification of regional tracer activity allows for comparisons 
between subjects, study protocols and scanners, all of which are crucial for 
researching new imaging modalities and tracer types. Absolute quantification of 
tracer uptake concentration can only be achieved through arterial blood sampling to 
obtain the tracer time-activity curve. This requires insertion of arterial lines so that 
multiple blood samples can be analysed during scanning (Gjedde 2001). SUV was 
developed as a means to achieve semi-quantitation in PET imaging. By correcting for 
isotope decay time, patient weight (or body surface area) and injected dose, an 
activity concentration can be calculated. 
  
PET imaging with FDG is often used in the assessment of treatment response to 
cancer therapy. Changes in SUV within the tumour over time are used as an indicator 
of treatment response. The SUVMAX is often utilised, which is defined as the hottest 
voxel within the tumour volume (Vanderhoek et al. 2012). The SUVMAX has gained 
popularity in clinical settings, largely due to the ease with which it can be identified 
and the simplicity in the way in which it is defined. However, high variance is a 
concern, owing to the fact that the measurement is only taken in a single voxel. 
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The SUVPEAK was proposed to attempt to reduce this degree of variability by taking 
the average uptake of a number of voxels (Wahl et al. 2009). SUVPEAK can be 
broadly defined as an ROI that is considered to be indicative of the highest uptake 
part of the tumour. The SUVPEAK is usually normalised to background uptake, the 
method of which varies depending on the tumour type and location within the body. 
The shape and size of the ROI can also vary depending on the imaging modality and 
tumour site. The PERCIST guidelines (Wahl et al. 2009) were developed to increase 
the degree of uniformity in the way in which SUVPEAK is defined and calculated, 
these guidelines were used for this body of work. According to the PERCIST 
guidelines, the SUVPEAK is the 1cm
3
 sphere of highest average activity inside the 
tumour mass, normalised to background (healthy tissue) uptake, which results in a 
value that quantifies how different the uptake in the tumour volume is from that 
which is seen in healthy tissue.  
 
1.6 Outline of Thesis 
 
This research is comprised of work performed on two different sets of patient data. 
Each Chapter is its own self-contained body of work, and is laid out as such, 
containing chapter-specific sections from literature review to conclusion. 
 
Chapters Two and Three are based on a data set acquired at the Western Australian 
PET centre at Sir Charles Gairdner Hospital, Perth. As part of a study into treatment 
method optimisation in recurrent glioma, 34 patients were subjected to a range of 
structural and functional brain imaging. The PET tracers used for the work, although 
not new, are seldom seen in a clinical setting. Chapter Two focusses on the 
differences in retained activity measured at different post-injection time points for 
each of the tracers. Information of this type will become crucial for the development 
of standardised imaging procedures should these compounds become more 
commonly used in clinical settings. 
 
Chapter Three assesses the survival prediction utility of each of the PET tracers, as 
well as Gd- MRI. The assessment was made using a novel semi-automated process 
that quantifies the volume of elevated tracer uptake/gadolinium enhancement in the 
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tumour affected brain region. Optimisation of treatment planning and survival 
outcomes in recurrent glioma is heavily dependent upon reliable imaging of tumour 
tissue. Novel uptake quantification methods such as the ones used in Chapter Three 
aid in the assessment of various imaging modalities, and can increase their value in 
the post-treatment glioma setting. 
 
Chapters Four and Five utilise data from the Australian Imaging Biomarkers and 
Lifestyle (AIBL) and Alzheimer’s Disease Neuroimaging Initiative (ADNI) archives. 
In Chapter Four, two different methods of volumetric hippocampal masking are 
compared with regards to their ability to find uptake differences between 30-subject 
groups of healthy control (HC), mildly cognitively impaired (MCI), and AD subjects, 
based on FDG-PET uptake in the masked volume. Automated brain image 
assessment has the potential to build upon established clinical AD detection methods, 
with computationally efficient and reliable analysis techniques offering the potential 
to provide earlier and more accurate diagnoses. 
 
Chapter Five examines the utility of an optimised volumetric hippocampal mask as a 
stand-alone diagnostic tool for AD. The scenario in which a brain PET image is 
acquired without an accompanying volumetric MRI is included, as this is often the 
case in a clinical setting. Volumetric hippocampal masking may become a significant 
component of AD diagnosis if a future shift towards imaging and biomarker 
assessment eventuates in clinical practice. 
 
Chapter Six contains a summary and overview of the thesis content, and 
recommendations for expansion and continuation of this research in the future. 
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2 Optimisation of CMET-PET and FLT-PET Acquisition 
Time in Glioma patients 
 
2.1 Introduction and Literature Review 
 
Nuclear medicine studies require the implementation of a waiting period between the 
administration of an isotope and the commencement of imaging. The length of time 
between administration and imaging varies with modality, radionuclide and disease 
pathology. The reason for the waiting period is to allow sufficient time for the 
distribution of the radionuclide within the patient, so that the contrast between target 
and other/background tissue is maximised. 
 
FDG is the most commonly used PET tracer, with 
18
F having a half-life of 
110 minutes. Despite the widespread use of FDG, there is no gold standard 
consensus on the optimal post-injection waiting period for brain imaging, partially 
due to differences in uptake times between patients with varying age and BMI. Due 
to its relatively long half-life, the decay of the nuclide itself need not be of significant 
concern when considering post-injection time differences in the order of an hour. 
Imaging methodology can be altered to adjust the way in which volumes of interest 
are visualised, two such adjustments are dual time point imaging (Matthies et al. 
2002) and delayed imaging (Kubota et al. 2001). The European Association of 
Nuclear Medicine recommends a minimum post-injection wait time for FDG brain 
imaging of 30 minutes (Varrone et al. 2009), but times of 60-90 minutes are common 
(Delbeke et al. 2006).  
 
The 20 minute half-life of 
11
C means that ideal post-injection waiting times are likely 
to be much shorter for CMET than those used for FDG. A study by Herholz and 
colleagues (1998) used 31 subjects with various gliomas with a mixture of images 
taken pre- and post-treatment, and acquired PET data continuously for 60 minutes 
immediately after injection. Data were then reconstructed to produce two sets of 
images, one containing data from 0-30 minutes post-injection and another from 20-
60 minutes. SUVPEAK was utilised to quantify tumour-background contrast, which 
was defined as the average SUV of an 8mm diameter circle in the transaxial plane, in 
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the highest uptake area of the tumour. To account for inter-subject differences in 
healthy brain tissue uptake, the ratio of tumour SUVPEAK to the average SUV within a 
contralateral circle, mirrored about the mid-sagittal plane was taken (scaling 
processes of this nature are referred to as background normalisation from this point 
on). No significant differences in tumour-contralateral tissue uptake were found 
between the image frames. However, the researchers favoured the longer imaging 
delay time due to “… the possibility that a very early measurement could be biased 
by significant intravascular activity” (Herholz et al. 1998, p 1322).  
 
A study by Aki and colleagues (2012) that included 24 pre-treatment Glioblastoma 
Multiforme patients found that the normalised tumour SUV was significantly higher 
at an imaging time of 25-35 minutes than it was at 5-15, and 15-25 minutes. The 
background normalisation method employed was to use the mean SUV from a 
manually drawn ROI in the contralateral frontal cortex. The maximum voxel number 
within the tumour volume (SUVMAX) was used for the tumour SUV, a method which 
is often used due to the ease with which the maximum voxel can be identified. It is, 
however, prone to increased variability and lower reproducibility than the use of a 
volumetric SUVPEAK region centred over the area of highest uptake within the tumour 
volume (Wahl et al. 2009). 
 
A study by Chen and colleagues (2005) comparing FDG and FLT for PET brain 
tumour imaging acquired FLT data using a 75-minute dynamic acquisition protocol 
starting immediately post-injection, to produce 5 x 1, 4 x 5, 2 x 10, and 6 x 5 minute 
frames. These images were acquired for 11 post-treatment patients with a range of 
gliomas. SUVPEAK was defined as the mean SUV within the highest uptake 20% of 
voxels in the tumour region; background normalisation was performed by taking the 
ratio of the SUVPEAK to the uptake in the contralateral cerebellar tissue. The tumour-
background contrast “… peaked slightly after 5-10 min following injection and 
remained constant through the 75-min scan” (Chen et al. 2005, p 948). The 
conclusion drawn was that “… imaging can commence shortly after tracer injection 
and 35 min of imaging is sufficient to obtain excellent image quality” (Chen et al. 
2005, p 950). No quantitative analysis aimed at distinguishing between time points 
was presented. 
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Another study by Jacobs and colleagues (2005) also imaged glioma patients using 
FLT at multiple time points on a mixture of pre and post-treatment gliomas. The 
frames were: 6 x 10s, 3 x 20s, 2 x 30s, 2x 60s, 2 x 150s and 16 x 300s. A circular 
8mm diameter ROI in the axial plane was placed in the area of highest uptake and 
background normalisation was performed by taking the ratio to the contralateral 
8mm circle. Reported findings in regards to tumour-background contrast were in 
accordance with (Chen et al. 2005). 
 
2.2 Materials and Methods 
 
2.2.1 Subjects and Imaging 
 
CMET-PET images from 12 (mean age 60, age range 39-73, eight males and four 
females) and FLT-PET images from 18 (mean age 60, age range 36-77, 13 males and 
5 females) stage III-IV glioblastoma multiforme patients from Sir Charles Gairdner 
Hospital (SCGH) were included in this research, after consulting with their 
oncologist and giving written informed consent. Patients were excluded from the 
research if they were pregnant, had a medical contraindication to MRI or PET 
imaging, or if their clinician considered them too cognitively impaired to give 
informed consent. Each subject was given standard treatment at SCGH, in 
accordance with the Stupp schedule (Stupp et al. 2005). This schedule involves 
surgical debulking/biopsy, followed by radiotherapy and three cycles of 
temozolomide chemotherapy, and Gd enhanced T1 and T2 weighted MRI around the 
time of the final chemotherapy cycle.  
 
PET tracers were synthesised at the R.A.P.I.D laboratories, Medical Technology and 
Physics, in SCGH. FLT “… was produced using the Tracerlab MX Synthesis module 
(GE) with commercially obtained disposable cartridge hardware kits (“ABX-FLT 
Hardware Kit for GE TracerLab MX Synthesizer (Cartridge version) for the 
Synthesis of [18F]-FLT,” #K662TM) and reagents (“ABX-FLT Reagents Kit for GE 
TracerLab MX Synthesizer (Cartridge version) for the Synthesis of [18F]-FLT,” #K-
653TM) purchased from ABX. 25mg BOC-FLT vials were also obtained 
commercially from ABX (“ABX-FLT Reagents Kit for GE TracerLab MX 
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Synthesizer (Cartridge version) Boc-FLT, Precursor for [18F]-FLT,” #K-653TM-P)” 
(P. Gibbons, SCGH Radiochemist, Personal Communication, 30/09/2014). CMET 
“was produced using the C11 Pro Synthesiser (iPhase Technologies) with 
commercially obtained disposable cartridge hardware kits (iPhase-11C Pro 
Disposable Hardware Kit) and reagents obtained from ABX including 1mg L-
homocysteine precursor” (P. Gibbons, SCGH Radiochemist, Personal 
Communication, 30/09/2014). 
 
Subjects fasted for a minimum of four hours prior to the intravenous CMET 
administration, which was performed through a cannula inserted into a peripheral 
vein; the administered dose was adjusted for patient weight [300 MBq x body surface 
area (m
2
)]. No subject preparation was required for FLT imaging. FLT 
administration was identical to CMET, with the exception of dose, which was 100 
MBq x body surface area (m
2
). CMET and FLT PET studies were performed within 
seven days of each other and within two weeks of the MRI. 
 
Volumetric MRIs were acquired on a Phillips Acheiva 3T scanner at SCGH. Images 
were acquired at 3T field strength in the sagittal plane, pixel size 1x1 mm
2
, slice 
thickness 1 mm, matrix size 256x256 pixels. 
 
PET/CT images were acquired on a Siemens Biograph/Sensation 16 slice PET/CT 
scanner at the WA PET Centre, at SCGH. Patients were positioned in the head first, 
supine position. CMET imaging was performed using four consecutive 10 minute 
acquisitions, beginning between five and 15 minutes post-injection. PET images 
were acquired in the axial plane, matrix size 168 x 168, pixel size 2.03 x 2.03 mm, 
slice thickness 2 mm, 82 slices, and Gaussian conv kernel 5 mm FWHM. For 
attenuation correction, an axial CT was performed immediately prior to the first PET 
acquisition with the following specifications: 120 kVp, 150 mAs, 512 x 512 matrix, 
pixel size 0.59 x 0.59 mm, slice thickness 3 mm, slice separation 2 mm, collection 
diameter 500 mm, reconstruction diameter 300 mm. The FLT protocol differed from 
that used for CMET in that there were two separate 15 minute PET acquisitions, 
beginning between 10-20 and 70-80 minutes post-injection. Each FLT acquisition 
was attenuation corrected using a CT taken immediately prior to the acquisition; the 
same CT acquisition parameters used for the CMET scan were employed. 
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2.2.2 Image Processing 
 
Raw PET image voxels were converted to standardised uptake values (SUV) 
(Bq/mL) in accordance with the vendor neutral pseudocode (20120928) developed 
by the Quantitative Imaging Biomarkers Alliance SUV Technical Subcommittee 
(QIBA) (Kinahan et al. 2012). 
 
 The series acquisition time, injection time, injected dose (Dinj), and patient weight 
(w) were acquired from the DICOM header. The decay time (∆t) is the difference 
between the series acquisition time and the injection time. The decay factor (DF) at 
the start of the acquisition was calculated using: 
 
2
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Where 
2
1t is the radionuclide’s physical half-life. An SUV factor (SF) can then be 
found by: 
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SUV conversion factors were calculated using a Matlab script, which can be found in 
Appendix 1. 
 
 Several stages of spatial registration were performed to align all of the PET and MR 
images to a standard space. The FreeSurfer (Martinos Centre for Biomedical 
Imaging, http://surfer.nmr.mgh.harvard.edu/) routine mri_convert was used to 
convert the image DICOMs into FSL (Smith et al. 2004) Nifti format.  
 
CMET Inter-acquisition patient movement correction was performed using the FSL  
(Smith et al. 2004) routine MCFLIRT (Jenkinson et al. 2002). This involved the 
calculation of rigid body transforms (six degrees of freedom) to co-register the 20, 
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30, and 40 minute acquisition to the 10 minute acquisition. Information in the Nifti 
headers was used to translate the origin of the 10 minute acquisition to co-register it 
with the attenuation correction CT. 
 
All CTs were co-registered with each of their intra-subject MRIs using a six degrees 
of freedom rigid body transformation with the FSL (Smith et al. 2004) routine FLIRT 
(Jenkinson et al. 2002). 
 
The T2 MRIs were co-registered to the McConnell Brain Imaging Centre (Montreal 
Neurological Institute (MNI), McGill University Montreal) 152 nonlinear 6
th
 
generation T1 1mm resolution brain template using a 12 degree of freedom affine 
transformation with FLIRT (Jenkinson et al. 2002). The co-registration between the 
T2 subject MRIs and the T1 MNI template was superior to that for the T1 subject 
MRI-MNI. Co-registration of the T1 subject MRI to the MNI template was achieved 
through a six degree of freedom rigid body registration to the T2 image. This process 
is illustrated in Figure 13. 
 
 
Figure 13, A schematic representation of the image co-registration process for the glioma study 
cohort. 
 
 
The transformation matrices that led to a PET-MNI or T1-MNI registration were 
concatenated so that a single transform could be used for each image. This resulted in 
image volumes only being resampled once to minimise resampling errors.  
 
2.2.3 Defining the SUVPEAK and Performing Background Normalisation 
 
SUVPEAK was defined as the 1cm
3
 sphere of highest average activity inside the 
tumour mass, in accordance with the PERCIST criteria  (Wahl et al. 2009). This was 
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found by manually defining a tumour VOI using the MNI co-registered MRIs and 
relevant PET image, then employing a python (Python Software Foundation, version 
2.7) script (Appendix 2) to search the VOI for the central voxel of a 1cm
3
 sphere in 
which the average SUV is maximised. 
 
A contralateral 1cm
3
 sphere was used for the background healthy tissue 
normalisation. The contralateral sphere was found by employing a reflection about 
the mid-sagittal plane, which is parallel with the Y-Z plane in MNI template space. 
The CMET SUVPEAK was normalised to background uptake by taking the ratio of the 
SUVPEAK to the average uptake in the contralateral sphere. Due to the very low 
uptake of FLT in healthy brain tissue, FLT background normalisation was performed 
by subtracting the mean of the contralateral sphere from the SUVPEAK. This was 
performed as the SUVPEAK/background ratio is greatly affected by a small change in 
a very small denominator. Figure 14 illustrates the background normalisation 
procedure: the green rectangles represent the search VOI for this subject. This is 
overlaid onto the T1 MRI and 10 minute CMET PET image, which has been 
thresholded to indicate the location of the uptake peaks (which are well contained 
within the green VOI to ensure the global tumour maximum is found). The light blue 
circle indicates the SUVPEAK volume, and the dark blue circle is the region used for 
background normalisation. 
 
 
Figure 14, An illustration of the SUV PEAK normalisation process. A subject T1 MRI is overlaid with 
the areas of highest CMET uptake (red-yellow). The green rectangle is the SUVPEAK search VOI, 
inside of which the SUVPEAK volume is seen (light blue circle). The contralateral background 
normalisation volume is the dark blue circle. 
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2.3 Results 
 
Figure 15 presents a line plot overlaid with a box and whisker plot showing the 
Normalised SUVPEAK at each post-injection CMET time point, each subject is 
represented by a single coloured line. 
 
 
Figure 15, A boxplot of the raw normalised CMET SUVPEAK data, overlaid with line plots 
representing each subject. 
 
In order to more easily identify the time point differences at group level, inter-subject 
normalisation was performed by subtracting each subject’s mean uptake across all 
time points from their uptake at each time point. The results are presented in Figure 
16. 
 
 39 
 
 
Figure 16, A boxplot of the mean subtracted normalised CMET SUVPEAK data, overlaid with line 
plots representing each subject. 
 
Repeated measures ANOVA with Tukey’s all-pair comparisons was conducted on 
the raw data to determine whether there was a significant difference between time 
points. Statistically significant differences were found between the 20 and 40 minute 
(p < 0.01) and 10 and 40 minute (p < 0.001) time points. 
 
Figure 17 and Figure 18 are graphical displays of the FLT data, utilising the same 
methods depicted in Figure 15 and Figure 16 for the CMET data. 
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Figure 17, A boxplot of the raw normalised FLT SUVPEAK data, overlaid with line plots 
representing each subject. 
 
A two-sided paired t-test found that there was a statistically significant difference 
between the time points in Figure 17 (p<.005). 
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Figure 18, A boxplot of the mean subtracted normalised FLT SUVPEAK data, overlaid with line plots 
representing each subject. 
 
 
2.4 Discussion 
 
The tumour-background contrast as defined on CMET-PET was significantly higher 
at 10 and 20 minutes than at 40 minutes post-injection in this group of post-treatment 
glioblastoma multiforme patients. Consequently, the recommended post-injection 
time is less than 40 minutes. Longer post-injection times ranging from 20-60 minutes 
have been recommended in previous studies (Aki et al. (2012); Herholz et al. 
(1998)). However, those studies used different methods to quantify normalised peak 
tumour uptake that are more prone to operator error and lack of reproducibility (see 
section 2.1). The small sample size (n=12) in this research is of concern, and repeat 
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studies with larger samples are required to achieve increased certainty in the results. 
A single attenuation correction CT was acquired for all four CMET-PET imaging 
time points. Rigid body transformation was employed to minimise movement 
artefacts between acquisitions, however it is possible that small attenuation 
correction errors were introduced as a result of imperfect movement compensation 
during imaging. 
 
The significance in the FLT images between the 15 and 75 minute time points differs 
to those noted in previous studies (Chen et al. (2005); Jacobs et al. (2005)), which 
found a slight increase in tumour-background contrast at 5-10 minutes and that 
uptake remained fairly constant up until 75 minutes post-injection. However, a lack 
of temporal statistical analysis in the aforementioned studies makes it impossible to 
quantify the level of agreement between the results. The aforementioned studies also 
calculated background healthy tissue normalisation by taking the ratio of the tumour 
SUV ROI to a healthy tissue ROI. Given that very low FLT uptake is seen in healthy 
brain tissue where there is no BBB disruption, the method used for this study was to 
subtract the tumour SUV PEAK from the contralateral normalisation volume to 
avoid large changes in the normalised SUV PEAK resulting from a small change in 
the background uptake. Further work is required to make a more precise 
recommendation regarding the ideal post-injection time point for the commencement 
of glioma imaging with FLT; however, it is recommended based on these results that 
it should occur at less than 75 minutes. 
 
Counter-intuitively, image co-registration between the T2 subject MRIs and the T1 
MNI template was superior to that of the T1 subject MRIs; this was possibly due to 
extreme pathology having a greater effect on the intra-modality cost function. An 
affine transformation was used to co-register each subject T2 MRI to the T1 MNI 
template, due to the fact that a closer registration was achievable with an affine 
transformation than with rigid body. Complete removal of yaw and roll tilt was 
essential to the background normalisation process, as calculating the placement of 
the contralateral SUV PEAK sphere was performed via a reflection about the mid-
sagittal plane, which is parallel with the Y-Z plane in MNI space after co-
registration. 
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This method for the determination of a Normalised SUV PEAK region is a 
computationally efficient, largely automated process that can be applied to a range of 
isotopes and imaging modalities. The combination of spatial registration and 
reflection about the mid-sagittal plane for background uptake normalisation 
circumvents the need for manually marking anatomical VOIs, this in turn requires 
significant expertise and time, and is prone to reproducibility errors.  
 
There were some limitations to the method used for SUV background normalisation. 
Any lesions where the SUV PEAK was within 6mm of the mid-sagittal plane could 
not be included in this work, as the tumour and contralateral regions would be at 
least partially sampling the same volume. Patients with bilateral lesions could only 
be included if the region used for background normalisation was healthy tissue. One 
possible method of circumventing this issue would have been to use a VOI within the 
cerebellum for background normalisation. Substantial uptake peaks often exist 
outside the brain for both CMET and FLT, which are obviously not of interest for 
glioma imaging. Separating these peaks from those within the brain can be extremely 
difficult and potentially impossible for lesions that are close to the skull. 
 
2.5 Conclusion 
 
CMET and FLT continue to show utility in glioma imaging, both for pre-treatment 
tumour staging and radiotherapy guidance, as well as in post treatment quantification 
of treatment efficacy and pseudoprogression. In order for these radionuclides to be 
used regularly in a clinical setting, information regarding temporal changes in 
tumour-background contrast will be important for establishment of imaging 
procedures. A semi-automated method was utilised to determine the tumour-
background contrast in a group of post-treatment gliobastoma multiforme subjects. 
CMET images were acquired at 10, 20, 30 and 40 minutes post-injection, and the 
contrast was significantly higher at 10 and 20 minutes than at 40 minutes. FLT 
images were acquired at 15 and 75 minutes post-injection, and the contrast at 15 
minutes was significantly higher than at 75 minutes. It is therefore recommended that 
imaging of glioma patients using CMET and FLT should commence prior to 40 and 
75 minutes post-injection respectively.  
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3 Survival Rate Analysis of Gd-MRI, CMET-PET, and 
FLT-PET in Glioma Patients 
 
3.1 Introduction and Literature Review 
 
The ability to differentiate between healthy tissue, viable tumour mass, and treatment 
related tissue effects such as necrosis and oedema is essential to maximise the 
efficacy of cancer treatment. The extremely invasive nature and radial growth pattern 
of gliomas contribute to a high percentage of treatment failure and tumour recurrence 
(Wirth et al. 2011), partially due to the difficulty in correctly identifying and 
removing viable tumour tissue. 
 
The most commonly used clinical treatment for glioma is surgical debulking (if 
possible) followed by chemo-radiotherapy (Stupp et al. 2005). This can produce a 
range of tissue effects, including necrosis and disruption of the blood brain barrier, 
which can be mistaken for actual tumour progression using Gd-MRI (Brandsma et al. 
2008). This phenomenon is known as pseudoprogression, and it is thought to occur in 
20-30% of cases (Brandsma and van den Bent 2009). The ability to recognise 
treatment-related effects and correctly identify the extent of any tumour recurrence is 
crucial to providing an accurate prognosis. It can also improve patient outcomes by 
allowing for planning of more appropriate follow-up treatment. Used in conjunction 
with structural radiologic imaging, functional imaging using CMET-PET and FLT-
PET may improve the sensitivity and specificity of post-treatment clinical 
assessment. 
 
There is evidence to suggest an SUV peak ROI to contralateral background uptake 
ratio in CMET-PET can be used to evaluate post-treatment high grade brain tumour 
recurrence and predict survival (Van Laere et al. 2005), and that it is superior to 
FDG-PET or T1 Gd-MRI for this purpose (Tripathi et al. (2012); Singhal et al. 
(2012)). CMET PET tumour uptake has also shown utility in predicting survival 
outcome in low grade glioma (Ribom et al. 2001). An optimal tumour/contralateral 
uptake ratio of 1.5 has been determined for the differentiation of tumoural and non-
tumoural lesions using CMET-PET (Herholz et al. 1998). This threshold has been 
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suggested as a means of defining viable tumour volume in order to track the success 
of chemotherapy over time (Herholz et al. 2003).  
 
Studies using multiple FLT-PET images taken during and post-treatment have shown 
a correlation between within-patient treatment response (a reduction in the tumour 
SUVPEAK over time) and increased patient survival time (Hoeben et al. 2013). This 
method of predicting survival time in cancers of the head and neck has produced 
better results than similar methods using Gd enhanced MRI (Chen et al. (2007); 
Schwarzenberg et al. (2012)). There have been attempts to use inter-subject 
differences in tumour uptake as measured by FLT-PET SUV analysis at a single time 
point to discriminate between treatment related effects and genuine progression, and 
to predict survival time that have failed to produce statistically significant results 
(Spence et al. 2009). 
 
Longitudinal survival data is available for a group of glioma patients that have 
undergone standard clinical treatment and follow-up imaging with FLT-PET, 
CMET-PET and volumetric Gd-MRI. This provides an opportunity to investigate 
each modality’s utility in survival time prediction based on volumetric thresholding 
of the tumour affected region. 
 
3.2 Materials and Methods 
 
3.2.1 Subjects and Imaging 
 
The initial patient cohort from which the data was taken is the same as described in 
section 2.2. CMET-PET images from 23 (mean age 58, age range 36-77, 16 males 
and seven females), FLT-PET images from 24 (mean age 57, age range 34-77, 17 
males and seven females), and T1 weighted Gd-MRI images from 26 (mean age 56, 
age range 34-77, 19 males and seven females) subjects were included. The 15 minute 
and 20 minute post-injection scans were used for FLT-PET and CMET-PET 
respectively. This allowed for the largest amount of data to be included (due to some 
inconsistencies with scanning times), whilst using delay time points that were found 
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to produce the highest tumour to background contrast using the normalised SUV 
PEAK method described in Section 2. 
 
3.2.2 Image Processing 
 
All images were normalised to the 1 mm
3 
resolution MNI 152 T1 MRI template 
using FSL (Smith et al. 2004), as outlined in Section 2.2. A modality-dependent 
thresholding method was then employed in an attempt to define a viable tumour 
volume.  
 
To establish and demarcate a viable tumour volume in the CMET-PET images, a 
method that enabled contralateral background normalisation on a voxel by voxel 
basis across an entire hemisphere was used. Firstly, the image volume was masked 
using the FSL (Smith et al. 2004) MNI space brain mask, to remove any counts 
detected outside the brain volume. Secondly, the image was divided along the mid-
sagittal plane to delineate between the two hemispheres: tumour and background. 
These first two steps are shown in Figure 19 (Part A). The background volume was 
then flipped and overlaid onto the tumour volume so that a tumour/contralateral 
comparison could be made at the voxel level. Figure 19 (Part B) shows the resultant 
viable tumour volume. Voxels with a tumour/normal ratio of greater than 1.5 were 
considered viable tumour tissue. This ratio has been found to maximise sensitivity 
and specificity for defining viable tumour tissue (Herholz et al. 1998). Two subjects 
whose tumour affected tissue volume crossed the mid-sagittal plane were excluded 
from the study, as background normalisation using the tumour/background 
hemisphere technique was not possible. 
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Figure 19, (Part A): Brain masking the PET images and dividing them into L and R hemispheres to 
allow for calculation of tumour to background uptake, (Part B): The resultant viable tumour mass, 
as seen on the 20 minute CMET scan.  
 
The method used for defining viable tumour volume using the FLT-PET images was 
the same as for CMET, with one exception. Rather than the ratio, absolute difference 
in voxel numbers was used to compare FLT hemispheres. A ratio was not used for 
FLT as very low background uptake meant that the ratio could be significantly 
distorted by small variations in background SUV. The method used to find the 
optimal tumour/normal SUV difference for the FLT-PET images is outlined in 
Section 3.2.3. 
 
A manual threshold was applied to each of the Gd-MRI images at a level that 
appeared to best separate areas of enhancement from background tissue. This 
threshold was not the same for all images as it was established on a case by case 
basis; the optimal threshold varied with inter-subject differences in signal intensity 
throughout the brain. The images were still masked with the MNI template to remove 
uptake that was external to the brain itself. As well as the MNI masking, a VOI mask 
was employed around the tumour region on the MRI images, to minimise inclusion 
of Gd enhancement that was not related to BBB disruption in the tumour region. 
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Figure 20 shows the viable tumour volume that was selected for a subject in the 
study using this technique. 
 
 
Figure 20, (Part A): A Gd enhanced T1-MRI taken from the study group, (Part B): The same 
image highlighting the volume used as a VOI mask drawn around the tumour region, (Part C): The 
green tissue was defined as viable tumour tissue using the manual thresholding technique. 
 
3.2.3 Optimisation of Viable Tumour Volume Identification Threshold 
in FLT-PET 
 
To determine the optimal tumour/background difference threshold to identify viable 
tumour volume for the FLT-PET images, receiver operating characteristic (ROC) 
curve analysis using survival at the median post-surgery survival time was employed. 
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A series of ROC curves were produced for tumour/background SUV difference 
thresholds between 0.1 and 0.7 for the FLT-PET images. Each ROC curve tested the 
effect that variation of the tumour volume cut-off between “small” and “large” had 
on the correlation between tumour size and survival at the median post-surgery 
survival time for the group (78 weeks). Censored subjects were included in the 
calculation of the median; their survival time was calculated as the time between 
their surgery and the present. They all survived longer than the median time, 
ensuring their inclusion would not affect the median value regardless of their actual 
survival time. The area under each ROC curve (AUC) was calculated and used to 
decide which absolute difference normalisation threshold was superior. Figure 21 in 
Section 3.3 is a graphical display of the ROC curves for each tumour/background 
SUV difference threshold. Table 1 in Section 3.3 shows the AUC values calculated 
for each threshold. For all ROC analyses, a true positive was defined as a subject that 
had a viable tumour volume larger than the cut-off, and who died earlier than the 
median survival time for the group.  
 
The immediately aforementioned process was only necessary for FLT-PET. The 
tumour-background uptake ratio of 1.5 used to define viable tumour mass in CMET-
PET was based on another study (Herholz et al. 1998), and the difference between 
enhancement and background volume in Gd-MRI was already clearly delineated 
(Figure 20). 
 
3.2.4 Viable Tumour Volume Optimisation for Each Modality 
 
An optimal cut-off volume for each modality to distinguish between subjects with a 
“large” or “small” viable tumour volume was established. This was achieved by 
ROC curve analysis, this time involving each modality. As in the previous 
comparison of ROC curves for the FLT-PET images, each of these were testing the 
effect that variation of the tumour volume cut-off between “large” and “small” would 
have on the correlation between tumour size and survival at the median post-surgery 
survival time for the group.  The cut-off point was selected based on the point on the 
curve that minimised the Euclidean distance to the point at which both sensitivity 
(Se) and specificity (Sp) = 1. Figure 22 and Figure 23 in Section 3.3 show the 
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median survival ROC curves for CMET-PET and FLT-PET respectively. Figure 24 
in Section 3.3 shows the median survival ROC curve for Gd-MRI; there were two 
points on the Gd-MRI curve that minimised the distance to the point at which both 
Se and Sp = 1. 
 
Once the required thresholds were calculated, Kaplan Meier survival plots (Kaplan 
and Meier 1958) displayed the results graphically, and the Log Rank Test (Peto and 
Peto 1972) was used to quantify differences in survival times between the groups for 
each modality. Kaplan Meier survival plots and log rank tests were completed using 
the R packages GGally and SurvDiff (R Core Team 2015). 
 
3.3 Results 
 
3.3.1 Optimisation of Viable Tumour Volume Identification Threshold 
in FLT-PET 
 
The ROC curves for all tested thresholds of tumour/background difference for the 
FLT-PET images during the optimisation process are presented in Figure 21. Table 1 
lists the AUC values for each threshold. The tumour/background SUV difference 
threshold of 0.2 was used for the survival analysis as it had the highest AUC. 
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Figure 21, ROC curves for all FLT background normalisation thresholds between 0.1 and 0.7. 
Median group survival time was used as the status variable. 
 
Threshold 0.1 0.2 0.3 0.4 0.5 0.6 0.7 
AUC 0.594 0.693 0.685 0.468 0.441 0.454 0.461 
Table 1, The AUC values calculated for each FLT background normalisation threshold ROC curve. 
 
3.3.2  Viable Tumour Volume Optimisation for Each Modality 
 
The ROC curves that illustrate the effect that variation of the tumour volume cut-off 
between “large” and “small” would have on the correlation between tumour size and 
survival at the median post-surgery survival time for the group are reflected in 
Figures 22-24.  Each figure is labelled with the chosen cut-off point. 
 
 52 
 
 
Figure 22, The median survival ROC curve for CMET-PET for tumour-background  SUV ratio > 
1.5, including the point on the curve that is closest to Sp and Se = 1. 
 
 
Figure 23, The median survival ROC curve for FLT-PET for tumour-background  SUV absolute 
difference > 0.2, including the point on the curve that is closest to Sp and Se = 1. 
 
Se = 0.615 
Sp = 0.727 
Vol = 41.4 cm
3 
Se = 0.769 
Sp = 0.5 
Vol = 25 cm
3
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Figure 24, The median survival ROC curve for Gd-MRI enhancement, including the points on the 
curve that are closest to Sp and Se = 1. 
 
3.3.3 Kaplan Meier Survival Plots and Results of the Log-Rank Test 
 
Figures 25 and 26 present the Kaplan Meier plots for CMET-PET and FLT-PET, 
respectively. Two plots were produced for Gd-MRI, in accordance with the ROC 
analysis that showed two points on the curve that were equally well correlated with 
survival at the median survival time. 
 
Se = 0.615 
Sp = 0.538 
Vol = 14.5 cm
3 
Se = 0.538 
Sp = 0.615 
Vol = 20 cm
3 
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Figure 25, A Kaplan Meier survival plot for CMET-PET viable tumour volume, the delineation 
between ‘small’ and ‘large’ tumour mass was set at 25 cm3. 
 
Figure 26, A Kaplan Meier survival plot for FLT-PET viable tumour volume, the delineation 
between ‘small’ and ‘large’ tumour mass was set at 41.4 cm3. 
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Figure 27, A Kaplan Meier survival plot for Gd-MRI enhancement volume, the delineation between 
‘small’ and ‘large’ tumour mass was set at 14.5 cm3. 
 
 
Figure 28, A Kaplan Meier survival plot for Gd-MRI enhancement volume, the delineation between 
‘small’ and ‘large’ tumour mass was set at 20 cm3. 
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The Log-Rank test (Peto and Peto 1972) was used to determine statistical 
significance between the groups for each image type. Only CMET-PET produced a 
difference that was significant (p < 0.05). The results are summarised in Table 2. 
 
Image type CMET-PET FLT-PET Gd-MRI (14.5 cm3) Gd-MRI (20 cm3) 
p-value 0.021 0.066 0.227 0.163 
Table 2, A summary of the results of the Log-Rank test performed on the survival data from each 
KM plot. 
 
3.4 Discussion 
 
Despite its widespread use in initial glioma diagnosis and therapy follow-up work, 
radiologic (primarily Gd-MR) imaging has been shown to have little utility in the 
differentiation of post-treatment tumour recurrence from treatment-related trauma 
and necrosis (Brandsma and van den Bent 2009). In order to improve the diagnostic 
accuracy of post-treatment glioma imaging, alternative modalities continue to be 
investigated in clinical research. Previous studies that pursued similar lines of 
investigative enquiry used longitudinal follow-up imaging as a means to assess 
treatment response via intra-subject changes in SUV, and used that as the factor 
which is analysed with regards to survival time (Herholz et al. (2003); Hoeben et al. 
(2013)). CMET PET has given superior outcomes to both FLT and Gd-MRI in 
previous studies attempting to predict survival outcomes in glioma (Singhal et al. 
(2012); Tripathi et al. (2012)). This study found that post-treatment tumour volumes 
on Gd-MRI and FLT-PET were not predictors of survival, in keeping with previous 
research. CMET-PET tumour volumes were found to be a statistically significant 
predictor of survival. 
 
A potential pitfall in the ROC curve method used for threshold optimisation was 
highlighted during the Gd-MRI data analysis, with two points on the curve having 
identical distances to the top left hand corner of the plot (Figure 24). Since neither 
threshold was a significant predictor of survival, the issue was not pursued further. If, 
however, a decision had to be made regarding choice of threshold in such a scenario, 
one way of coming to a conclusion may be to change the way in which sensitivity 
and specificity are weighted. Studies concerned with cervical and breast cancer 
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diagnosis have found that that patients believe that sensitivity is the most important 
factor; that is, patients would rather be falsely diagnosed with cancer than falsely 
given a clean bill of health (Basen-Engquist et al. (2007); Schwartz et al. (2000)).  
 
Achieving a high degree of accuracy when manually thresholding a high contrast 
tumour volume on Gd-MRI is made difficult by the fact there can be significant 
concentrations of Gd immediately outside the brain. Masking the image using the 
MNI brain mask template was performed to overcome this problem, but image co-
registration is never perfect; there were occasions where a high contrast ring or 
crescent was seen at the outer edge of the brain as a result of small errors in the 
registration. As seen in Figure 20, a manual VOI was used to reduce the number of 
erroneous voxels included, but this could not always remove all extraneous high 
contrast voxels. Manual editing was not performed, as this would lead to reliance on 
the operator to decide where the uptake outside the brain ceased and the uptake 
inside the brain began; a proposition which is nearly impossible for tumours near the 
skull. A similar problem was noted for the PET images; a small error in the image 
alignment may result in a similar false inclusion of high relative uptake at the edge of 
the image. The fully automated nature of this analysis method is greatly 
advantageous with regards to its potential clinical applications. It is possible that 
individual tumour volumes may be identified with greater accuracy if each were 
manually edited to remove the previously mentioned artefacts. However, this would 
alter the very nature of the technique itself and greatly diminish its potential clinical 
utility. Manual modification of the tumour volumes may introduce inter-operator 
variability and human error into the method, as well as introducing the requirement 
for tedious and repetitive editing, thus it was not part of the investigation. 
 
There were two subjects whose tumours crossed the mid-sagittal plane forcing their 
exclusion from the PET analysis due to the nature of the hemisphere based 
background normalisation; this was not an issue for the MRI contrast enhancement 
selection method. 
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3.5 Conclusion 
 
Current radiologic imaging techniques continue to fail to adequately distinguish 
treatment-related tissue effects from tumour progression in glioma, leading to the 
requirement for other modalities and analysis methods to provide a solution. A semi-
automated method was used to examine the utility of FLT-PET, CMET-PET and Gd- 
MRI for survival prediction based on viable tumour volume. CMET-PET was the 
only image type found to be a survival predictor.  
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4 Diagnostic Performance of Manual Versus Automated 
Hippocampal Masking in Alzheimer’s Disease 
 
4.1 Introduction and Literature Review 
 
Reliance upon assessment of clinical symptoms alone in early AD diagnosis 
commonly results in diagnostic sensitivities and specificities of around 70%. 
Symptoms from conditions such as other dementias, depression, normal age-related 
neurodegeneration, and alcohol/drug use are frequently mistaken for AD in elderly 
patients (Blennow et al. 2015). It is hoped that the incorporation of imaging and 
biomarkers into clinical AD diagnosis can increase the rate at which a correct early 
diagnosis can be made. 
 
There can be significant variation in the acuteness of AD pathology between 
sufferers; different areas within the cerebrum are also affected with varying severity. 
The medial temporal lobe is an area which is very severely affected by AD. In 
particular, the hippocampus stands out as a substructure that is one of the earliest 
affected brain regions (Nestor et al. 2004). Accurate assessment of hippocampal 
tissue effects can potentially become a useful biomarker for clinical AD assessment. 
 
Large scale atrophy throughout the cerebral cortex can be clearly seen in vivo using 
structural MRI, as well as atrophy of some small structures such as the hippocampus 
(Apostolova et al. 2012). Corresponding reductions in regional glucose metabolism 
(MRglc) in large cortical volumes have been identified by studies using automated 
voxel based analysis (VBA) on FDG-PET images; however, these studies almost 
never find the expected reduction in hippocampal MRglc (Mosconi et al. 2005). This 
inability to detect reduced hippocampal MRglc is possibly due to the small volume 
of the hippocampus and the errors inherent in the spatial registration of 
comparatively low resolution PET images to an anatomical template. Manual ROI 
sampling, guided by coregistered MRI, has proven more effective at detecting 
reduced hippocampal MRglc. This method, though effective, has several drawbacks. 
Marking out manual ROIs of the hippocampus for an individual is laborious, and can 
only be reliably performed by someone with thorough knowledge of neuroanatomy. 
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Furthermore, patients are rarely given a volumetric MRI in a clinical setting. An 
optimised mask created using manually marked hippocampal peripheries on T1 
MRIs has been shown to be accurate in defining the hippocampus on spatially 
normalised FDG-PET images, and for detecting reductions in hippocampal MRglc in 
patients with Mild Cognitive Impairment (MCI) and Alzheimer’s disease (AD) 
(Mosconi et al. 2005).  
 
Some brain image processing programs such as FSL (Smith et al. 2004) feature a 
routine that can automatically segment cortical and subcortical structures within a 
volumetric T1 MR image, potentially circumventing the requirement for manual ROI 
marking in the analysis of brain substructures. The use of a fully automated 
hippocampal masking algorithm increases the ease with which very large data sets 
can be analysed, enabling the diagnostic capability of the method to be evaluated 
with greater statistical power. Furthermore, refinement and improvement of the mask 
as image technology improves can be conducted much more easily if repeated 
manual marking is not required. 
 
The study by Mosconi and colleagues (2005) demonstrated the utility of an 
optimised hippocampal mask, created by expert observers manually marking the 
hippocampus on 48 MRI studies, in identifying changes in hippocampal MRglc 
during the onset and development of AD. This Chapter compares the performance of 
a manually defined hippocampal mask with one that was formulated using an 
automated algorithm. An automated masking method allows for increased numbers 
of subjects to be included in the mask itself, and for easier redevelopment and 
refinement of the mask in the future. The two masks are then compared with regards 
to their capacity to differentiate between groups of AD, MCI and healthy control 
(HC) subjects. 
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4.2 Materials and Methods 
 
4.2.1 Image Cohort 
 
Images for this research were obtained from two different sources. 21 (7 AD, 7 MCI 
and 7 HC) Volumetric T1 brain MRIs from the CSIRO’s Australian Imaging, 
Biomarkers & Lifestyle Flagship Study of Ageing (AIBL, http://aibl.csiro.au/) (Ellis 
et al. 2009) were used for the creation of the manual hippocampal mask. AIBL MR 
images were collected using 1.5 T scanners and acquired in the sagittal plane as 1.2 
mm thick contiguous slices. The pixel size and slice thickness was 1.2 mm and the 
image matrix size was 256 x 240 pixels. These images were used for manual mask 
generation. 
 
A further 190 (51 AD, 66 MCI and 73 HC) subjects were selected from the 
Alzheimer’s Disease Neuroimaging Initiative online database (ADNI, 
http://www.adni-info.org/Home.aspx) (Mueller et al. 2005). These subjects had both 
volumetric T1 MRI and FDG-PET images taken. For inclusion in this analysis, 
images from the ADNI cohort were only considered if their volumetric T1 MRI and 
FDG-PET scans were taken no more than three months apart. ADNI MR images 
were 1.5 T, acquired in the sagittal plane as contiguous slices, pixel size 1.25 x 1.25 
mm, slice thickness 1.2 mm, matrix size 192 x 192 pixels. ADNI PET images were 
acquired in the axial plane, with a dynamic emission scan of six five-minute frames 
beginning 30 minutes post injection; images were reconstructed into a 128 x 128 
matrix with a 2 mm slice thickness and pixel size.  
 
All images were obtained in DICOM format. To enable spatial registration and 
automated hippocampal marking using FSL (Smith et al. 2004), images were 
converted to FSL nifti format using the FreeSurfer (Martinos Centre for Biomedical 
Imaging, http://surfer.nmr.mgh.harvard.edu/) routine mri_convert. 
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4.2.2 Hippocampal Mask Generation 
 
4.2.2.1 Manual Hippocampal Marking 
 
All 21 subjects (7 from each diagnostic category) drawn from the AIBL database 
comprised the manual masking cohort. ImageJ (RSB, National Institute of Mental 
Health) (Schneider et al. 2012) was used to facilitate the digital marking of the MRIs, 
which is depicted in Figure 29. The marking was conducted by a neuroradiology 
registrar at Royal Perth Hospital as follows: 
 
“Coronal MRI T1-MPRAGE 1mm thick slices were obtained for each patient 
perpendicular to the long axis of the hippocampus, which was used to individually 
draw regions of interest of both hippocampi. The neuroimaging specialists who 
performed this were blinded to the clinical status of each patient. Mapping 
commencing at the pes-hippocampus anteriorly was performed on every second slice 
over a twenty-slice volume for a total of 10 hippocampal measurements per mesial 
temporal lobe. The lateral hippocampal border was defined as the temporal horn of 
the lateral ventricle, the medial border as the ambient cistern, and the inferior border 
as the white matter of the parahippocampal gyrus.” (A. Law, Consultant Nuclear 
Medicine Physician, personal communication November 24, 2011). 
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Figure 29, A coronal outline of the hippocampus in the left hemisphere, made using the manual 
marking technique in ImageJ (RSB, National Institute of Mental Health). 
 
Manual marking was performed on every second coronal slice. However, a 
contiguous volume is required to delineate the whole hippocampus. In order to 
construct a contiguous volume from the marked coronal slices, the images were first 
re-sliced and viewed in the sagittal plane. A single iteration of the binary processing 
‘dilate’ and ‘erode’ functions built in to ImageJ was then used to form a contiguous 
volume. The dilate function works by assigning a value of 1 to every 0 value voxel 
that sits adjacent to a ‘1’ voxel. This has the effect of filling in small holes or spaces 
in a volume as well as expanding its outer perimeter. The erode function performs 
the opposite operation. The net effect is that small holes or spaces within a volume 
are filled in with minimal impact on the original outer perimeter. Figure 30 (Part A) 
shows the marked non-contiguous hippocampal slices and the contiguous volume 
formed after the implementation of the dilate and erode functions (Part B). 
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Figure 30, (Part A): Manually marked coronal hippocampal sections, viewed in the sagittal plane, 
(Part B): The continuous hippocampal volume formed by using the ‘dilate’ and ‘erode’ functions 
in ImageJ. 
 
4.2.2.2 Automated Hippocampal Marking 
 
100 subjects (21 AD, 26 MCI and 43 HC) were randomly selected from the ADNI 
cohort to form the automated mask. The FSL (Smith et al. 2004) subroutine FIRST 
(Patenaude et al. 2011) was used to automatically segment out the hippocampus on 
all subject MRIs from the ADNI database. The volume used to define the 
hippocampus on a subject MRI using FIRST can be seen in Figure 31. FIRST 
incorporates data obtained from manually labelled image sets to assist in forming an 
initial estimation of the spatial location of the subcortical structures to be segmented. 
A deformable virtual surface mesh for each structure was then calculated and 
optimised to form the substructure boundaries (Patenaude et al. 2011). 
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Figure 31, A sagittal view of a subject’s hippocampal volume, defined by FIRST. 
 
4.2.2.3 Montreal Neurological Institute Template Coregistration 
 
Nonlinear warping was used to spatially coregister all subject MRIs to the 
McConnell Brain Imaging Centre (Montreal Neurological Institute (MNI), McGill 
University Montreal) 152 nonlinear 6
th
 generation T1 2mm resolution brain template 
via a multi-stage process. The FSL (Smith et al. 2004) routine BET (Smith 2002) was 
used to strip the skull from around the brain volume. An approximate template 
alignment was then achieved using the FSL routine FLIRT (Jenkinson et al. 2002) to 
calculate a 12 degree of freedom affine transformation to the MNI brain template. 
The affine transformation was used to assist in the calculation of nonlinear warps, 
which were used to give a more precise template registration. The FSL routine 
FNIRT (Andersson et al. 2007) was used to calculate the nonlinear subject MRI-MNI 
template warps. Figure 32 illustrates the MRI spatial registration process. 
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Figure 32, (Part A): A native space subject MRI, (Part B): The MRI after skull extraction using 
BET, (Part C): The MRI after affine brain template registration using FLIRT, (Part D): The MRI 
after nonlinear spatial warping to the T1 MNI template using FNIRT, (Part E): The T1 MNI 
template. 
 
FIRST segmentation (Patenaude et al. 2011) marks a subject’s hippocampal volumes 
in the subject’s native image space; this allows for a subject’s MRI-MNI warp to be 
applied to the hippocampal volume to provide an MNI template space 
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transformation. Figure 33 illustrates the location of a subject’s hippocampus after 
transformation to the MNI template.  
 
 
Figure 33, The location of a subject’s FSL (Smith et al. 2004) marked hippocampus in MNI space 
after nonlinear warping to the MNI template. 
 
4.2.2.4 Hippocampal Mask Optimisation 
 
Once the hippocampal volume for each subject had been spatially warped to MNI 
space, a summation volume across all subjects in a cohort was created that showed 
the degree of hippocampal overlap at each voxel. The summation volumes for the 
manual and automated FSL (Smith et al. 2004) masks are shown respectively in 
Figure 34, Parts A and B. The process used to develop and optimise both masks 
draws upon the work of Mosconi and colleagues (2005). 
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Figure 34, (Part A): The summation volumes displaying the MNI space location of all hippocampal 
volumes for the manual markings, (Part B): The automated FSL (Smith et al. 2004) markings. The 
heat map corresponds to the degree of overlap at each voxel. 
 
It was critical to avoid incorrectly sampling non-hippocampal tissue within the mask. 
In other words, the maximisation of true positives (voxels included in the mask that 
are within the hippocampus for a given subject) was more important than the 
minimisation of false negatives (voxels that are not included in the mask but are 
within the hippocampus for a given subject).  
 
If this was the only consideration to be taken into account, then mask optimisation 
would be as simple as only sampling those voxels in MNI space that were shared 
between all subjects’ hippocampal volumes. However, as is discussed in Mosconi 
and colleagues (2005), the inter-subject variability in hippocampal anatomy means 
that increasing the sample size from which a mask is formulated will likely lead to a 
decrease in the number of voxels that are shared between all subjects. The use of 
such a small volume means that when applying the mask to a large set of subjects, 
the average counts sampled in an individual subject is highly susceptible to the 
inclusion of only a very small number of non-hippocampal voxels.  
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Resampling statistics, in particular the bootstrap, can be used to simulate how a mask 
volume might vary if a very large number of subjects were sampled. The Bias-
Corrected and Accelerated Percentile (BCa) method of bootstrapping (Efron and 
Tibshirani 1993) was used to assess mask volumes by degree of overlap, in order to 
assess the theoretical stability of the masks’ volume if they were drawn from very 
large sample sizes. The bootstrapping procedure is outlined in Appendix 3. The 
largest volume stable mask was selected as the optimal mask. 
 
4.2.3 Quantification of Hippocampal MRglc 
 
The FDG-PET images of the 90 ADNI database subjects who were not used for the 
automatic mask generation (30 HC, 30 MCI and 30 AD) were used to compare the 
performance of the manual and automatic masks.  
 
The ADNI imaging protocol for FDG-PET brain images is a “dynamic 3D scan 
consisting of six-5 minute frames” with acquisition commencing 30 minutes post-
injection (ADNI 2006, p 11). The normal FDG-PET acquisition protocol at our 
institution is for a single frame 30 minute acquisition; an equivalent image set was 
generated from the ADNI PET for each subject as follows. 
 
The FSL (Smith et al. 2004) routine mcflirt (Jenkinson et al. 2002) was used to 
perform rigid body intra-subject co-registration of the dynamic image sequence to 
the first frame of the sequence, removing the effect of any patient movement 
between the frames. The 6 co-registered images were then averaged to form a single 
FDG-PET image volume for each subject in the cohort. This average image was used 
for all further processing. 
 
Intrasubject (MRI – PET) image alignment for the ADNI images was performed via 
a six degree of freedom transformation (rigid body) using the FSL (Smith et al. 2004) 
routine FLIRT (Jenkinson et al. 2002). Once a subject’s PET was aligned with their 
MRI, the nonlinear MRI-MNI warps calculated during the automatic hippocampal 
mask development were then applied to transform the PET images to the MNI 
template space. This process is depicted in Figure 35.  
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Figure 35, (Part A): A subject FDG-PET volume in its native space, (Part B): The subject PET and 
MRI volumes after intra-subject MRI co-registration, (Part C): The subject PET and MRI volumes 
after nonlinear spatial registration with the MNI template. 
 
Differences in inter-subject FDG uptake and inter-scanner sensitivity differences 
were accounted for by scaling each PET voxel using the average uptake in the pons, 
as pons metabolism is relatively unaffected in AD (Minoshima et al. 1995). A pons 
VOI was constructed such that its borders sat within the boundaries of the pons on 
the 2mm T1 MRI MNI template, to minimise the chances of erroneously including 
extra-pontine tissue on a PET image due to spatial normalisation errors. Figure 36 
depicts this volume, which was defined by using an ImageJ macro (included in 
Appendix 4) to outline a series of transaxial polygonal ROIs that fell within the pons. 
The volume of the pons VOI was 1.6 cm
3
. This volume was used to select the pons 
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on PET images that had been spatially warped to template space. Pons normalisation 
was achieved by applying a scaling factor to an image volume so that the average 
voxel number inside the pons VOI was 10000. 
 
 
Figure 36, The VOI used to represent the pons for scaling of a subject’s FDG-PET images. 
 
After pons normalisation, an ImageJ macro was used to determine the average 
normalised hippocampal metabolism for each of the remaining 90 subjects from the 
ADNI database (30 HC, 30 MCI and 30 AD) using both hippocampal masks. This 
macro is included in Appendix 5. 
  
4.3 Results 
 
4.3.1 Mask Optimisation and Bootstrapping 
 
If the hippocampal marking and spatial normalisation procedures were both perfect, 
then the degree of overlap at every hippocampal voxel in the summation volumes 
shown in Figure 34 would be 100%. However, only seven voxels (56 mm
3
) from the 
manually marked data and 27 voxels (216 mm
3
) from the FSL (Smith et al. 2004) 
automated data were common to all subjects. 
 
It was found that the smallest (100% overlap voxels only) masks for both the manual 
and automated masks were unstable; that is, they fell outside the 95% BCa 
confidence limit (Efron and Tibshirani 1993) (further details regarding the 
bootstrapping calculations can be found in Appendix 3). Therefore, the automated 
and manual mask volumes included the voxels that were shared between 99 or more 
of 100 (99%) subjects in the FSL (Smith et al. 2004) cohort, and 20 or more of 21 
subjects (95%) in the manually marked cohort as these were the smallest masks that 
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fell within the 95% BCa confidence limit. The size of these masks were 68 voxels 
(544 mm
3
) and 21 voxels (168 mm
3
) for the automated and manual masks 
respectively. 
 
4.3.2 Quantification of Hippocampal MRglc Using the Masks 
 
A comparison of the averaged pons normalised MRglc within each of the masks, 
displaying differences between each diagnostic category, is shown in Figure 37. 
 
 
Figure 37, Boxplots showing the group level differences between diagnostic category for both the 
manually marked and FSL (Smith et al. 2004)  hippocampus masks. 
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p-values 
Groups Manual Mask FSL Mask 
AD-MCI < .005 < .005 
AD-HC < .0005 < .0005 
MCI-HC >.05 >.05 
Table 3, The significance (Tukey’s HSD) of differences in normalised hippocampal MRglc between 
AD, MCI and HC groups for both manual and FSL (Smith et al. 2004) masks. 
 
Group level differences in the pons normalised masks counts were investigated using 
Tukey’s HSD Test, which were calculated using the statistics package R. No 
significant difference between the MCI and HC groups were found for either mask (p 
> 0.05). However, differences between the AD-HC and AD-MCI groups for both 
masks were significant at the 0.0005 and 0.005 levels respectively. Figure 38 
illustrates the correlation in MRglc measured using the two different masks for each 
individual. A high degree of correlation was found (r = 0.96, p < 0.0001 using 
Pearson’s product moment correlation in R). These results show that the performance 
of the masks is equal at both the individual and group level. 
 
 
Figure 38, A graphical representation of the degree of correlation between MRglc levels measured 
in each individual between the automated and manual hippocampus masks. 
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4.4 Discussion 
 
Quantification of neurodegeneration due to AD without the use of imaging involves 
significant confounding factors, which include the potential influence of other 
conditions and difficulties in establishing a baseline for expected cognitive 
performance. Brain imaging allows for better understanding of patterns of 
degeneration that are AD-specific, some of which become evident before the onset of 
clinical symptoms. FDG-PET is a widely available imaging modality that has 
demonstrated utility in research settings in identifying patterns of neurodegeneration 
that can be specifically attributed to AD (McKhann et al. 2011). 
 
A study by Mosconi and colleagues (2005) that used a manually defined  mask of the 
anterior portion of the hippocampus known as the head or “pes” (see Figure 10), 
found significant MRglc differences between groups of AD and HC brains, as well 
as HC and MCI brains, but not between MCI and AD. The results from that study are 
different to this study with regards to the relative MRglc seen in the MCI group. This 
research found there to be no significant difference in MRglc between the MCI and 
HC groups, and a significant difference between the AD and MCI groups.  
 
There can be differences in the manner in which MCI is defined between studies. For 
a subject to be diagnosed with MCI in the Mosconi and colleagues (2005) study, they 
needed to have a Mini Mental State Examination (MMSE) score of > 24, and a 
Global Deterioration Scale (GDS) (Reisberg et al. 1982) score of 3. Likewise, to be 
considered MCI by ADNI, subjects needed an MMSE score of > 24. However, they 
also needed to have a memory complaint, and objective memory loss measured by 
education adjusted scores on the Wechsler Memory Scale Logical Memory II 
(Wechsler 1987), as well as a Clinical Dementia Rating (CDR) (Morris 1993) of 0.5  
(ADNI 2008). To be diagnosed as MCI by the Australian Imaging, Biomarkers and 
Lifestyle (AIBL) study, a participant must have reported memory difficulties (either 
directly or through an informant). If the subject had already been clinically diagnosed 
as MCI before entering the AIBL study, they were required to demonstrate a score 
that was 1.5 or more standard deviations below the age-adjusted mean on at least one 
neuropsychological task to be considered MCI by AIBL. Monthly clinical review 
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panel meetings were held, during which study participants who entered the study as 
HC participants could be re-diagnosed as MCI. In order for this to happen, they had 
to score at least 1.5 standard deviations below the age-adjusted mean in two or more 
cognitive tests (Ellis et al. 2009). The fact that different studies take varying 
approaches to the diagnosis of MCI is indicative of the level of uncertainty 
surrounding the condition itself. The difference in diagnostic criteria identified 
between the Mosconi and colleagues (2005) study and the ADNI study probably had 
an effect on the overall distribution of MCI MRglc rates measured in this research.  
 
The process of manual hippocampal marking can be extremely resource intensive 
and time consuming, and requires expert observers. Establishing a large manually 
marked cohort of brain images would be very difficult for this reason, and the 
manual marking protocol used in this research was adjusted to try and save time for 
the neuroradiology registrar performing the marking. Only every second coronal 
slice was marked starting at the anterior hippocampal boundary, this method was 
considered sufficient due to the regular shape of the hippocampus along the anterior-
posterior direction (Figure 11). Only ten slices were marked in total, which meant 
that the anterior 20 mm portion of each hippocampus was included in the manual 
mask. This marking length is in line with previous studies employing manual 
hippocampal segmentation and spatial warping, which found that superior diagnostic 
accuracy was achieved for the larger anterior portion of the hippocampus, and that 
use of the smaller tail section led to increased registration errors (De Santi et al. 
2001). As can be seen in Figure 34, this made the manually marked mask 
significantly smaller than the FSL (Smith et al. 2004) mask, however it does not 
appear to have had a large effect on the overall significance values noted in Table 3 
and on the MRglc values recorded for each individual in the study (Figure 38). 
 
Spatial warping of brain images to the MNI template was occasionally problematic, 
particularly for the AD brains. Two of the hallmarks of AD progression are greatly 
enlarged ventricles and significant cortical atrophy. These two factors make close 
registration to a template such as the MNI 152 template (which is based on healthy 
young adult brains) significantly more difficult and time consuming, and resulted in 
the exclusion of a large number of brain images that were downloaded from the 
ADNI database due to the inability to produce a good spatial warp. Elderly brain 
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templates are now available to improve the spatial normalisation of heavily atrophied 
brains to a standard space (Evans et al. 2012) The use of such a template may 
improve spatial normalisation results in any future research in this area. 
 
4.5 Conclusion 
 
Both the automated and manual processes of hippocampal masking were capable of 
detecting differences between groups of AD and MCI, and AD and HC brains. They 
were not able to detect differences between groups of MCI and HC brains. The 
automated system of hippocampal marking using FSL (Smith et al. 2004) is far less 
time consuming and can employ batch processing to include very large numbers of 
subjects, as well as increasing the ease with which the mask can be modified and 
updated as imaging technology improves. Furthermore, the automated marking 
method circumvents the need for the anatomical expertise required for manual 
marking. It appears that there is a difference in pons normalised hippocampal MRglc 
between populations of AD and either MCI or HC brains. However, there is large 
variation between individuals of the same diagnostic category. This variation may 
limit the usefulness of the technique as means of AD diagnosis; nonetheless, it may 
find future utility as part of a battery of tests for AD diagnosis and evaluation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 77 
 
5 Clinical Utility of Hippocampal Masking in the 
Diagnosis of Alzheimer’s Disease and Mild Cognitive 
Impairment 
 
5.1 Introduction and Literature Review 
 
Biomarkers that reliably detect the presence of AD pathology and can differentiate 
between HC, MCI, and AD could be used to complement or even supersede clinical 
cognitive assessment, and potentially lead to earlier and more accurate diagnostic 
outcomes. This Chapter examines the clinical utility of the hippocampal mask 
developed in the previous Chapter in the differential diagnosis of AD and MCI. 
 
5.1.1 Diagnostic Threshold Selection for Diseases with Three States 
 
For diseases in which there exist only two states (i.e. no precursor/transitional phase), 
a diagnostic test need only discriminate between healthy and diseased individuals. 
The Receiver Operating Characteristic (ROC) was developed as a means to facilitate 
the selection of a cut-off threshold to delineate between healthy and diseased 
individuals based on the result of a screening test or diagnostic assessment. The 
threshold can be shifted to reflect differences in the relative importance of sensitivity 
and specificity.  
 
A popular method for selecting a diagnostic threshold to discriminate between binary 
disease states is the Youden Index (Youden 1950). The formula to calculate the 
Youden Index ‘J’ at a particular cut-off point ‘t’ is 
 
                                                             𝑱(𝒕) = 𝑺𝒆(𝒕) + 𝑺𝒑(𝒕) − 𝟏                   (3) 
                                                  (Youden 1950)      
 
Where ‘Se’ is sensitivity and ‘Sp’ is specificity. The maximum achievable Youden 
Index result is 1, which is attained if a cut-off point yields both perfect sensitivity 
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and specificity. The minimum is zero, which is the result of a diagnostic test that 
fares no better than random chance.   
 
For diseases such as AD that have an intermediate stage exhibiting some or all of the 
disease symptoms with reduced severity, a single ROC curve is not appropriate. 
Several different approaches have been taken to address the issue of classification in 
the scenario in which there are more than two groups. Diri and Albayrak’s (2008) 
research used a number of different group classification methods on a thyroid 
dysfunction data set. The data included subjects exhibiting hypo, normal, and 
hyperthyroid function. They extended the ROC curve to cater for the three group 
case by using ‘cobweb’ plots that served as a means to visualise the errors across the 
diagnostic categories. Another study aimed to use two novel methods (closest to 
perfection and max volume) (Attwood et al. 2014) for threshold selection in the three 
class setting, and found that they were statistically indistinguishable from a three 
group generalised Youden Index model (Nakas et al. 2010).  
 
The Three Group Youden Index proposed by Luo and Xiong (2013)  can be used to 
find multiple optimal cut-off thresholds to delineate between healthy, transitional, 
and diseased individuals (Luo and Xiong 2013). Under the assumption of a normal 
distribution within each diagnostic category for subject test results, the three group 
method aims to define two thresholds: t-, and t+. The three resultant groups (D
-
, D
0
, 
and D
+
) then describe the subjects that are diagnosed as healthy, intermediate, and 
diseased respectively.  
 
Three different variables are then be used to quantify the suitability of the thresholds 
with regards to each of the three disease states. Sp(t-) is the proportion of diseased 
individuals whose measurement was below t-. Se(t+) is the proportion of healthy 
individuals whose measurement was above t+, and Sm(t-,t+) is the proportion of 
transitional subjects that fell between the thresholds t- and t+.  
 
The optimal Youden Index thresholds are found by maximising the three group 
Youden Index, J(t-,t+), which is defined as 
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                                            𝑱(𝒕−,𝒕+) =
𝟏
𝟐
[𝑺𝒑(𝒕−) + 𝑺𝒎(𝒕−, 𝒕+) + 𝑺𝒆(𝒕+) − 𝟏]    (4) 
                                (Luo and Xiong 2013) 
 
The three group Youden Index is again expressed so that its value can only range 
from 0 to 1. If a test perfectly separates the three diagnostic categories, then the three 
group Youden Index is 1; whereas a three group Youden Index of 0 indicates that the 
test is no better than random chance at separating the groups. In the case of two of 
the three diagnostic groups demonstrating very little separation, the dimensions of 
the problem can be reduced to allow for a more simplistic ROC curve-style 
assessment of a single threshold. 
 
The Youden Index gives equal weighting to both sensitivity and specificity. 
However, the two parameters may be weighted differently depending on the purpose 
of testing. For example, a test that is used to screen for a deadly infectious disease 
may apply a greater weighting to sensitivity than specificity, as the unnecessary 
quarantining of a healthy patient may be preferable to the release of an infected 
patient. However, if a screening test is used for a condition in which the follow-up 
diagnostic testing or treatment is very expensive or carries health risks, specificity 
may be weighted more heavily than sensitivity in order to avoid the expense or 
health risks incurred by unnecessarily performing further testing or treatment on 
healthy patients (Carneiro et al. 2011).  
 
5.1.2 Chapter Summary 
 
The utility of the hippocampal mask was investigated in two different scenarios. The 
first was when a suitable volumetric MRI was available to guide the MNI template 
registration of each PET image. An initial analysis of the three group data set that 
was based on MNI template spatial warping driven by a coregistered volumetric T1 
MRI (Section 4.2) was performed using the three group Youden Index proposed by 
Luo and Xiong (2013). The second scenario accounts for the commonly encountered 
clinical setting, in which a volumetric MRI is not taken alongside a brain PET. An 
analysis of hippocampal MRglc was performed for ADNI PET images that were 
spatially warped to an MNI space PET template without the use of MRI guidance, in 
order to assess the potential utility of the method in the MRI-less case. Upon review 
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of the quantification variables, further analysis was conducted on two group data sets 
(AD vs Non AD), which was formed by combining the MCI and HC groups. 
 
5.2 Materials and Methods 
 
Patient data consisted of volumetric T1 MRI and FDG-PET brain images from the 
Alzheimer’s Disease Neuroimaging Initiative (ADNI) database. Data from 190 
subjects were used, including 51 AD, 66 MCI, and 73 HC subjects. Images were 
spatially normalised to the FSL (Smith et al. 2004) Montreal Neurological Institute 
(MNI) T1 MRI template through a two-stage process (approximate linear alignment 
followed by precise non-linear warping) that was driven by template registration with 
the subject MRI. A randomly selected cohort of 100 subjects (21 AD, 36 MCI and 43 
HC)  was used to develop an optimised hippocampal mask in MNI space, based on 
subject hippocampal volumes defined on the subject MRIs using the FSL (Smith et 
al. 2004) routine FIRST (Patenaude et al. 2011). Patient imaging details, the method 
used to construct the optimised hippocampal mask, and details of the MRI driven 
spatial normalisation procedures are in Section 4.2. The optimised hippocampal 
mask was used to sample the pons normalised hippocampal MRglc on PET images 
of the 100 subject mask development cohort and to calculate cut-off thresholds to 
best delineate between the diagnostic categories using the Three Group Youden 
Index (Luo and Xiong 2013). The ensuing MRglc cut-off thresholds were then 
applied to the remaining 90 subjects, a test cohort consisting of 30 AD, 30 MCI, and 
30 HC subjects.  
 
The mask development cohort data was then re-structured into two groups, AD and 
Non-AD, by combining the HC and MCI data. Receiver Operator Characteristic 
(ROC) curve analysis was utilized to calculate a threshold to delineate between the 
two newly formed diagnostic classes. The threshold was then applied to the 90 
subject test cohort. 
 
Volumetric MRI is often unavailable in a clinical setting. This scenario was 
simulated through the use of a separate spatial normalisation procedure, in which the 
PET images for each patient were spatially normalised to an MNI space H2O
15 
PET 
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template from the software package Statistical Parametric Mapping (SPM) (Friston 
2007). Subject PET images were spatially normalised to the PET template using a 
similar two-step process to that used for the MRI driven spatial normalisation. 
Firstly, a 12 degree of freedom affine transformation was calculated using the FSL 
routine flirt (Jenkinson et al. 2002) to calculate an approximate alignment with the 
template. Secondly, precise template registration was achieved via calculation of 
nonlinear warps using the FSL routine fnirt (Andersson et al. 2007). The process of 
PET driven template registration is illustrated in Figure 39. 
 
 
Figure 39, (Part A): A native space ADNI PET image, (Part B): The PET image after the 
application of a 12 DOF affine transform, (Part C): The PET image after the application of a series 
of nonlinear warps to co-regiester it with (Part D): The SPM (Friston 2007) PET template.  
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The Statistics software program R (R Core Team 2015) was used for the statistical 
calculations. The package DiagTest3Grp (Luo and Xiong 2012) was used to compute 
the Three Group Youden Indices, and pROC (Robin et al. 2011) and Optimal 
Cutpoints (Lopez-Raton et al. 2014) were used and perform ROC analysis.  
 
5.3 Results 
 
5.3.1 MRI Driven Template Registration Data Set 
 
Figure 40 shows the distribution of pons normalised hippocampal MRglc in the 100 
subject mask development cohort, as measured by the optimised hippocampal mask. 
An outlier (greater than three times the inter-quartile range from the edge of the box) 
is present in the AD group. Inspection of the subject images revealed that a severe 
level of hippocampal atrophy resulted in the mask sampling the ventricle rather than 
the brain tissue. This is further explained in Figure 49, Section 5.4. All further 
analysis of the 100 subject mask development group excluded the outlier, the box 
and whisker plot of the data set with the outlier removed can be seen in Figure 41. 
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Figure 40, A box and whisker plot displaying the pons normalised hippocampal MRglc for the 100 
subject mask development cohort. 
 
 
Figure 41, A box and whisker plot displaying the pons normalised hippocampal MRglc for the 
mask development cohort after the removal of the outlier from the AD group. 
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Figure 42 is a scatter plot and box and whisker plot displaying the spread of the pons 
normalised hippocampal metabolism data for the three diagnostic categories. The 
horizontal dashed lines indicate the t+ and t- cut-off thresholds that maximised the 
Three Group Youden Index. 
 
 
Figure 42, A graphical representation of the three group Youden Index and cut-off threshold 
selection for the mask development cohort. 
 
The value for each of the group classification probabilities were: 
Sp(t-): 0.56 
Sm(t-,t+): 0.31 
Se(t+): 0.69 
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The cut-off thresholds were: 
Lower Threshold (t-): 0.98 
Upper Threshold (t+): 1.06 
 
These classification probability values indicate the rate at which the thresholds are 
able to correctly classify each diagnostic category. Sp(t-), Sm(t-,t+), and Se(t+) relate 
to AD, MCI, and HC respectively. The low value of Sm(t-,t+) indicates that the 
majority of the MCI subjects fell outside of the ‘central’ region that exists between 
the thresholds in Figure 42. The lower and upper cut-off thresholds from the Three 
Group Youden Index analysis (t+ and t- in Figure 42) were applied to the 90 subject 
test group to assess their diagnostic efficacy; the results can be seen in Table 4. 
 
 
AD MCI HC Total 
Correct 26 11 23 60 
Incorrect 4 19 7 30 
Table 4, The results of applying the cut-off thresholds from the MRI driven spatial normalisation 
mask development data set Three Group Youden Index analysis to the 90 subject test data set. 
 
The thresholds correctly categorised AD and HC patients 87% and 77% of the time, 
respectively. The MCI categorisation had poor efficacy, with only 37% of MCI 
subjects being correctly diagnosed. Of the subjects that were misdiagnosed, 12 fell 
above the t+ cut-off threshold, meaning that more MCI subjects were classified as 
HC than were classified as MCI. 
 
The Three Group Youden Index method was unable to produce a cut-off threshold 
that could reliably separate MCI subjects from the other diagnostic classes. Due to 
this, and the fact that the distribution of MCI subjects is similar in appearance to the 
HC subject distribution (as can be seen in the location of the inter-quartile boxes in 
Figure 42), a reduction in dimensionality was performed so that there were only two 
groups involved: AD and non-AD (including 20 and 79 subjects respectively for the 
mask development cohort). Analysis of the two group data set included ROC curve 
computation and the calculation of the Youden Index to determine the best value of 
normalised hippocampal metabolism to discriminate between the two new groups. 
The results of these methods can be seen in Figure 43 and Figure 44. 
 
 86 
 
Figure 43 is a boxplot displaying the data set after it had been reduced down to two 
groups. 
 
 
Figure 43, A box and whisker plot illustrating the distribution of the two group pons normalised 
hippocampal metabolism data for the MRI driven mask development cohort. 
 
Figure 44 shows the ROC curve that was calculated based on the dimension reduced 
data set. The area under the curve (AUC) was 0.79. 
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Figure 44, The ROC curve displaying the variation of sensitivity and specificity with cut-off 
threshold selection for the reduced dimension data set (AD vs non-AD), as well as the point on the 
curve that optimises the Youden Index for the MRI driven mask development cohort. 
 
The Youden Index optimal cut-off threshold for pons normalised hippocampal 
metabolism for the two group data set was 1.03. The sensitivity and specificity at this 
threshold were 0.80 (95% CI 0.56-0.89) and 0.76 (95% CI 0.65-0.81) respectively. 
The point at which this threshold sits on the ROC curve can be seen in Figure 44. 
 
The cut-off threshold from the mask development cohort was then applied to the 90 
subject test cohort after re-structuring into AD and Non AD classes (including 30 and 
60 subjects respectively); the results are summarised in Table 5.  
 
 
Optimal Youden 
Index Threshold 
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True Positive 25 
False Negative 5 
True Negative 37 
False Positive 23 
Sensitivity (95% CI) 0.83 (0.65-0.9) 
Specificity (95% CI) 0.62 (0.48-0.68) 
Table 5, The results of applying the cut-off thresholds from the MRI driven mask development data 
set ROC curve Youden Index Analysis to the 90 subject test data set, including 95% confidence 
intervals for sensitivity and specificity. 
 
 
5.3.2  PET Driven Template Registration Data Set 
 
In order to draw comparisons between the MRI driven spatial warping procedures 
and its PET only equivalent, the PET driven data were analysed in the same manner 
as the MRI driven data. Figure 45 is a box and whisker plot displaying the 
distribution of pons normalised hippocampal metabolism for the mask development 
cohort (after removal of the outlier seen in Figure 40).  
 
 
Figure 45, A box and whisker plot displaying the pons normalised hippocampal MRglc for the 
mask development cohort after the removal of the outlier from the AD group, based on the PET 
driven spatial warp. 
 
 89 
 
Figure 46 is a scatter plot and box and whisker plot displaying the distribution of the 
pons normalised hippocampal metabolism data for the three diagnostic categories 
from the PET driven spatial warp. The horizontal dashed lines indicate the t+ and t- 
cut-off thresholds that maximised the 3 group Youden Index. 
 
 
Figure 46, A graphical representation of the three group Youden Index and cut-off threshold 
selection for the mask development cohort PET driven spatial warp. 
 
The value for each of the group classification probabilities were: 
Sp(t-): 0.46 
Sm(t-,t+): 0.09 
Se(t+): 0.70 
The cut-off thresholds were: 
Lower Threshold (t-): 1.07 
Upper Threshold (t+): 1.09 
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The optimal Three Group Youden Index thresholds were then applied to the 90 
subject test data set, the results of this can be seen in Table 6.  
 
 
AD MCI HC Total 
Correct 21 1 21 43 
Incorrect 9 29 9 47 
Table 6, The results of applying the cut-off thresholds from the PET driven 100 subject mask 
development data set Three Group Youden Index analysis to the 90 subject test data set. 
 
The thresholds correctly categorised AD and HC patients 70% of the time. The MCI 
categorisation had extremely poor efficacy, with only 3% of MCI subjects being 
correctly diagnosed. As noted with the MRI driven spatial warp data, a majority of 
the misdiagnosed MCI subjects were classified as HC; this was the case for 18 of the 
29 misclassified subjects. 
 
Figure 47 shows the distribution of the PET driven spatial normalisation data after 
the reduction in dimensions to AD vs Non AD. 
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Figure 47, A box and whisker plot illustrating the distribution of the two group pons normalised 
hippocampal metabolism data for the PET driven mask development cohort. 
 
Figure 48 shows the ROC curve that was calculated, based on the data presented in 
Figure 47, including the point that corresponds to the optimal Youden Index cut-off 
threshold. The AUC was 0.62. 
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Figure 48, The ROC curve displaying the variation of sensitivity and specificity with cut-off 
threshold selection for the reduced dimension data set (AD vs non-AD), as well as the point on the 
curve that optimises the Youden Index for the PET driven 100 subject mask development cohort. 
 
The Youden Index optimal cut-off threshold for the data set was 1.13. The sensitivity 
and specificity at this threshold were 0.85 (95% CI 0.62-0.93) and 0.44 (95% CI 
0.33-0.50) respectively. The point at which this threshold sits on the ROC curve can 
be seen in Figure 48. 
 
 
 
 
 
 
Optimal Youden 
Index Threshold 
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The cut-off threshold from the mask development cohort was then applied to the 90 
subject test cohort, the results are summarised in Table 7.  
 
True Positive 25 
False Negative 5 
True Negative 29 
False Positive 31 
Sensitivity (95% CI) 0.83 (0.65-0.9) 
Specificity (95 % CI) 0.48 (0.35-0.55) 
Table 7, The results of applying the cut-off thresholds from the PET driven 100 subject mask 
development data set ROC curve Youden Index Analysis to the 90 subject test data set, including 
95% confidence intervals for sensitivity and specificity. 
 
5.4 Discussion 
 
For a diagnostic test or screening procedure to be used clinically, there must be a 
point at which an individual is considered to be disease positive/potentially disease 
positive. For some procedures, such as identifying potential lesions in mammography 
screening, this is not necessarily achieved through a binary quantification, but rather 
a conclusion reached by an individual upon inspection of the test results. For the 
mammography example, this is a radiologist reviewing a mammogram. For the 
purposes of determining the utility of the pons normalised hippocampal metabolism 
quantification method in diagnosing MCI and AD, a definitive quantification or cut-
off threshold(s) was sought for use in the formation of a diagnosis. The potential 
utility of the method was also investigated for the case in which no volumetric MRI 
is available to drive template spatial registration, as is often the case in a clinical 
setting. 
 
The presence of MCI, considered to be an intermediate “transition” state that can 
present before a subject progresses to AD (Albert et al. 2011), complicates the 
formation of a quantitative diagnostic threshold. Figure 40 presents the distribution 
of pons normalised hippocampal MRglc data for the 100 subject mask development 
cohort. There is an outlier in the AD group that has an MRglc measurement far 
below any others in the data set. Upon investigation of that subject’s images, it 
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became apparent that the optimised mask had erroneously sampled the lateral 
ventricles as well as the hippocampal tissue, a result of spatial registration errors 
caused by severe atrophy within the patient’s medial temporal lobe. This can be seen 
in Figure 49. No other subject brains were so severely affected by errors in spatial 
normalisation, so the outlier was removed and further analysis of the mask 
development cohort was conducted on the remaining subjects.  
 
 
Figure 49, Images of the MNI template spatially normalised subject brain that showed an 
abnormally low measurement of pons normalised hippocampal MRglc in Figure 40. (Part A): A 
trans-axial slice through the subject brain at the level of the hippocampus, (Part B): The same slice 
overlaid with the optimised automated FSL (Smith et al. 2004) hippocampal mask (yellow voxels), 
(Part C): The masked region at a higher magnification, (Part D): The mask voxels that fell within 
the lateral ventricles on the subject brain, rather than the hippocampus (red voxels). 
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5.4.1 MRI Driven Template Registration Data Set 
 
 A classic ROC curve cannot be easily used to identify multiple thresholds to 
delineate between more than two disease states. Although there isn’t a widely used 
ROC curve alternative for the three group case, the Youden Index has been expanded 
to allow for quantitative threshold calculation in this scenario (Luo and Xiong 2012). 
Figure 42 shows the results of the Three Group Youden Index calculation, which 
resulted in the identification of two thresholds (t- and t+) that optimised the Youden 
Index function (Equation 2). 
 
With reference to Figure 42 and the accompanying value for Sm(t-,t+) (0.31), it can 
be seen that it is not possible to reliably delineate between MCI and AD/HC subjects. 
As a result of this, and the fact that the majority of misdiagnosed MCI cases were 
classified as HC, the data were re-structured and the MCI and HC subjects were 
grouped together. 
 
The re-structuring of the data allowed for the creation of a classic ROC curve (Figure 
44), from which an optimal cut-off threshold was derived in order to separate the AD 
and Non AD groups. This threshold was then applied to the 90 subject test data set to 
evaluate its performance, the results of which are presented in Table 5. While the 
true positive rate of 83% is encouraging, the rate of false positives (38%) is too high 
for this method to have much utility on its own as a diagnostic tool. 
 
5.4.2 PET Driven Template Registration Data Set 
 
Figure 46 shows the results of the Three Group Youden Index calculation. The 
optimal Youden thresholds effectively eliminate the presence of the intermediate 
(MCI) diagnostic category. The fact that the highest overall Youden index was 
achieved by minimising the MCI category to a great extent is symptomatic of the 
lack of separation between the MCI and either the AD or HC groups. 
 
The AUC values for the AD vs non AD ROC curve in Figure 44 is higher than for 
Figure 48, indicating that the MRI driven warping procedure is superior to its PET 
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only equivalent for separating the two groups. Both techniques were able to diagnose 
AD in the 90 subject test cohort with the same sensitivity (83%). The MRI driven 
spatial normalisation method showed higher specificity (0.62, 95% CI: 0.48-0.68) 
than the PET driven equivalent (0.48, 95% CI: 0.35-0.55); however, this was not 
significant at the 95% confidence level. 
  
5.4.3 Summary 
 
In order for the MRI driven spatial registration method to be used clinically, a patient 
needs to have had a set of structural and functional images of the brain already 
acquired. The PET only registration method produced an ROC AUC value (0.62) 
that was inferior to that seen on the MRI driven registration (0.79). Neither of the 
data analysis methods produced results that warrant the use of the method as a stand-
alone screening procedure for AD. However, a process in which these images are fed 
through an algorithm that quantifies their pons normalised hippocampal metabolism 
and includes other biomarkers that can be automatically assessed and quantified, may 
increase the sensitivity and specificity seen from the testing. Examples of other 
potential biomarkers include hippocampal volume, amygdala metabolism and 
volume, and ventricle and overall brain volume. 
 
The method is limited in its potential clinical utility in part by the difficulty in 
accurate nonlinear registration of an atrophied elderly brain to a template based on 
healthy adult brains (the McConnell Brain Imaging Centre (Montreal Neurological 
Institute (MNI), McGill University Montreal) 152 nonlinear 6
th
 generation T1 1mm 
resolution brain template).  Only around one in two subjects yielded suitable spatially 
warped brain volumes for further analysis with minor modification of the warping 
process; manual adjustment was often required with regards to brain masking and 
fine tuning of the affine registration. Clinical use of this technique will probably be 
better served by the use of a more appropriate ‘elderly’ template, as the degree of 
spatial normalisation required for the average individual will be lower, likely leading 
to less discarded data and an improvement in the data that is available. 
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5.5 Conclusion 
 
To assess the utility of the pons normalised hippocampal metabolism quantification 
method in a clinical setting, several options for the formation of cut-off thresholds to 
delineate between the three diagnostic categories were investigated. Two different 
data sets were analysed; one that used a subject’s volumetric MRI to guide spatial 
registration, and another which relied solely on the use of their FDG-PET image. The 
Three Group Youden Index was calculated for each approach, and it was found that 
neither spatial registration method was able to separate the MCI subjects from the 
other diagnostic classes. 
 
Due to the inability to separate out the MCI subjects from the other diagnostic 
classes, the data were restructured. The MCI and HC groups were merged into a 
single ‘Non AD’ group which was then re-analysed with respect to the AD group. 
ROC curves were constructed for each method, and the Youden Index was calculated 
in order to determine an optimal cut-off threshold to separate the two groups. The 
MRI driven spatial warp was superior to the PET driven method with regards to 
AUC on the ROC curve and specificity when making a diagnosis using the optimal 
Youden Index threshold. 
 
In its current form, the method serves as a demonstration of the reduction in 
hippocampal metabolism between AD sufferers and healthy elderly people. 
However, the large variation between individuals limits the potential of the method. 
It may likely find greatest utility as part of a suite of automatically acquired 
biomarkers that combine to render an overall impression of cerebral health. 
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6 Conclusions and Future Work 
 
6.1 Summary and Evaluation 
 
Linear and nonlinear spatial registration of brain volumes to a standard template has 
formed the framework on which this research is developed. All images were spatially 
transformed to conform to the common space defined by the Montreal Neurological 
Institute (MNI) using FSL. The ability to conduct automated inter-subject 
comparisons at the voxel level across large groups of subjects is made possible by 
these pre-processing spatial registration steps to ensure they occupy the same 
standard space. 
 
A comparison of post-injection imaging times for two different PET radioisotopes 
(
11
Carbon-Methionine (CMET) and 3’-deoxy-3’-18Fluorine-Fluorothymidine (FLT)) 
in a group of post treatment glioma patients was conducted. The PERCIST 
guidelines (Wahl et al. 2009) were used to define a background healthy tissue 
normalised SUVPEAK volume. The highest average uptake within a 1cm
3
 sphere 
inside the tumour affected area was found in each PET image. Background uptake 
was represented by an identical sphere, located in the contralateral hemisphere, 
which was positioned by reflecting the highest uptake tumour sphere about the mid-
sagittal plane. The background normalised SUVPEAK was then defined in the CMET 
images as the ratio of the tumour/background average uptake spheres. In the FLT 
images, the difference in SUV between the spheres was used, due to the extremely 
low uptake of FLT regions in which the blood-brain barrier (BBB) remains intact. 
Tukey’s HSD test was used to compare the four CMET post-injection imaging time 
points (10, 20, 30, and 40 minutes) at the group level. A downwards trend can be 
seen in Figure 16 in Section 2.3; the tumour-background contrast at both 10 and 20 
minutes was found to be higher than at 40 minutes at the 99% confidence level. A 
two-sided paired t-test was used to compare the FLT imaging time points (15 and 75 
minutes post injection). Tumour-background contrast at 15 minutes was found to be 
significantly higher than at 75 minutes (p < 0.005). These results suggest that earlier 
imaging using these isotopes for this application (less than 40 and 75 minutes for 
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CMET and FLT respectively) may be important to maximise tumour-healthy tissue 
contrast.  
 
The same cohort of post treatment glioma patients was used in another investigation 
that sought to assess the utility of CMET-PET, FLT-PET and Gd-MRI to predict 
survival outcomes based on the volume of tissue that demonstrated 
uptake/enhancement that was significantly elevated above background (considered to 
be viable tumour volume for the modality). Each PET brain volume was divided 
along the mid-sagittal plane to create distinct hemispheres for tumour and 
background healthy tissue. CMET-PET background normalisation was performed for 
each voxel in the tumour hemisphere by taking the ratio with the contralateral voxel; 
voxels with a ratio of greater than 1.5 were considered viable tumour volume. The 
same process was used for background normalisation of the FLT-PET images, except 
the difference in SUV between tumour and background voxels was used for 
normalisation. FLT-PET tumour hemisphere voxels with an SUV difference that was 
greater than 0.2 above background were considered viable tumour volume. A manual 
thresholding process on the MR images was used to define the tissue volume that 
showed increased uptake due to Gd-MRI pooling in areas of blood-brain barrier 
disruption. ROC curve analysis was used to identify the optimal tumour volume 
threshold above which a subject’s survival would be less than the median survival 
time (78 weeks) of the cohort for each modality. Survival time differences for 
subjects with volumes below and above the optimal values were examined using a 
log-rank test. CMET-PET was the only modality to produce a significant difference 
between the small and large viable tumour volume groups at the 95% confidence 
level. FLT-PET and Gd-MRI are considered to be primarily agents that highlight the 
areas in which blood-brain barrier disruption has occurred. The results found in this 
investigation support this hypothesis, as high uptake/enhancement with these 
modalities did not have a significant correlation with survival, indicating that they’re 
not necessarily highlighting viable tumour volume. The results also indicate that 
CMET-PET may be an effective means of highlighting viable tumour volume in 
post-treatment glioma brains. 
 
The remainder of the work focussed on the validity and clinical utility of 
hippocampal glucose metabolism in FDG-PET as a diagnostic indicator for AD. 
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Large scale atrophy within the cerebral cortex, as well as smaller scale atrophy in 
structures such as the hippocampus, can be seen in AD patients using structural MRI 
(Apostolova et al. 2012). Research employing automated VBA methods can detect 
large scale MRglc reductions on FDG-PET images, but almost always fails to find 
MRglc reductions in the hippocampus (Mosconi et al. 2005). This discrepancy is 
likely due to the small volume of the hippocampus and the errors inherent in the 
spatial registration of comparatively low resolution PET images to an anatomical 
template. An optimised mask created using manually marked hippocampal 
peripheries on T1 MRIs has been shown to be accurate in defining the hippocampus 
on spatially normalised FDG-PET images, and for detecting reductions in 
hippocampal MRglc in patients with MCI and AD (Mosconi et al. 2005). In this 
research, two optimised hippocampal masks were compared. One was comprised of a 
small number (n = 21) of subjects whose hippocampi were marked manually on the 
subject MRIs, the other from 100 subjects that had been processed using an 
automated subcortical segmentation algorithm. The masks were compared with 
regards to their ability to find group level differences between the average pons 
normalised hippocampal metabolism in AD, MCI, and HC brains. It was 
demonstrated that the masks produced near identical results. Neither mask was able 
to separate the MCI from HC groups, but both found significant differences between 
AD and HC (p < 0.0005) and AD and MCI (p < 0.005) groups using Tukey’s HSD 
test. 
 
The potential clinical utility of hippocampal masking with regards to AD diagnosis 
was then investigated. The automated mask was chosen for this analysis, as it was 
considered more defensible from a reproducibility standpoint. The clinical utility of 
the mask was tested using MRI driven spatial warping of FDG-PET images to MNI 
space and, since volumetric MRI has frequently not been performed as a routine part 
of patient workup in a clinical setting, a comparative data set was created where the 
FDG-PET images were spatially warped directly to an MNI space PET template. An 
extension of the Youden Index for the three group case was used to assess the utility 
of a bi-threshold method for diagnosing an individual as either HC, MCI, or AD for 
the MRI-driven and PET-driven spatial warp data sets. Both spatial warping methods 
demonstrated an inability to separate MCI subjects from either AD or HC subjects.  
As a result, the subjects were spilt into two groups: AD and non-AD, to allow for 
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ROC curve analysis with a view to constructing a threshold that may find utility as 
an AD screening method. There were no differences between the methods in 
sensitivity or specificity with regards to AD diagnosis at the 95% confidence level. 
This method of automated hippocampal metabolism assessment, used as a screening 
process for identifying subjects that are at risk of AD, will likely only find utility as 
part of a suite of tests including other biomarkers such as hippocampal volume, 
overall brain volume, ventricular enlargement, and the presence of other AD 
biomarkers such as amyloid β protein plaques. 
 
6.2 Recommendations for Future Research 
 
Accurate identification of cancerous tissue in post-treatment glioma patients is an 
ongoing imaging problem. Future nuclear medicine imaging work will likely focus 
on radionuclides that can penetrate an intact BBB; imaging agents that cannot are 
unable to detect lesions outside the regions of BBB disruption. Furthermore, such 
agents potentially face difficulties in distinguishing elevated uptake due to tumour 
tissue to that which is due to diffusion alone. Another PET imaging agent that has 
shown utility in both pre- (Jansen et al. 2015) and post-treatment (Popperl et al. 
2004) glioma imaging, and which will continue to be the focus of future studies is O-
(2-18F-fluoroethyl)-L-tyrosine (FET).  
 
The image and survival analysis method used in Chapter 3 has the potential to be 
used in future longitudinal brain imaging studies. The high degree of automation of 
the method lends itself to studies involving large numbers of subjects through the use 
of batch processing. The technique will be utilised in the near future for image 
analysis in a FET-PET glioma imaging study at Sir Charles Gairdner Hospital, 
allowing for further refinement of the technique and assessment of its utility. 
 
Detecting differences in hippocampal metabolism between groups of HC, MCI, and 
AD patients using automated hippocampal masking in FDG-PET may have future 
utility as a clinical screening method. The potential of the method will be increased 
by improvements in image resolution, as well as an improved system of spatial 
registration. The use of an age range appropriate brain template such as the Elderly 
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Brain Template from the University of California Neuroscience Imaging Centre (San 
Francisco, CA) (http://sfnic.ucsf.edu/Brain_Template.html) will likely be beneficial 
for improving the accuracy of spatial registration. Furthermore, research into the 
combined use of other characteristic AD biomarkers such as increased ventricular 
volume, decreased cerebral and hippocampal volume, and Amyloid β protein plaque 
deposition may provide higher accuracy in predicting and diagnosing the disorder. 
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8 Appendices 
 
8.1 Appendix 1: SUV Conversion Factor Script 
 
© 2015 The MathWorks, Inc. MATLAB and Simulink are registered trademarks of 
The MathWorks, Inc. See www.mathworks.com/trademarks for a list of additional 
trademarks. Other product or brand names may be trademarks or registered 
trademarks of their respective holders. 
 
This Matlab script was written by Mr Ricki Nezich, Medical Physicist, Medical 
Technology and Physics Sir Charles Gairdner Hospital, Nedlands WA. 
 
% suvFactorTable looks at all of the folders beneath the 'baseFolder' 
% containing PET Dicom series, and creates an Excel file with a table of 
% SUV conversion factors for each series. The Excel file is saved in the 
% 'baseFolder'. 
 
function suvFactorTable(baseFolder) 
    % Preallocate Excel output cell array. 
    PRE_CELL_ROWS = 1000; 
    outputXls = cell(PRE_CELL_ROWS, 2); 
    outIndx = 0; 
     
    % Get all folders below 'baseFolder'. 
    disp('Collecting folders...'); 
    baseFolder = strrep(baseFolder, '\', '/'); 
    fList = FileList(baseFolder); 
    fList.collectSubFolders(); 
    folders = fList.getFileNames(); 
     
    % Process each folder. 
    for i = 1:length(folders) 
        % Get a vector of files contained in the folder. 
        folderName = strrep(folders{i}, '\', '/'); 
        FileStruct = dir(folderName); 
         
        % Calculate the SUV conversion factor from the first valid Dicom 
        % image in the series. 
        for j = 1:length(FileStruct) 
            fileName = FileStruct(j).name; 
            if length(fileName) >= 2 && strcmp(fileName(1:2), 'IM') 
                try 
                    suvFactor = getSuvFactor(fullfile(folderName, fileName)); 
                catch exception 
                    disp(exception.message); 
                    continue; 
                end 
                if suvFactor == 0 
                    break; 
                end 
                 
                outIndx = outIndx + 1; 
                 
                % Get the patient ID 
                patID = sscanf(folderName, strcat(baseFolder, '/%6c/%*s')); 
                fprintf('%s\nSUV factor: %f\n\n', fullfile(folderName, fileName), suvFactor); 
 
                % Write the information to the output cell array. 
                outputXls{outIndx, 1} = patID; 
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                [~, seriesName, ~] = fileparts(folderName); 
                outputXls{outIndx, 2} = seriesName; 
                outputXls{outIndx, 3} = suvFactor; 
                break; 
            end 
        end 
    end 
     
    % Write data to Excel file. 
    xlswrite(fullfile(baseFolder, 'SuvFactors'), outputXls(1:outIndx, :)); 
end 
 
% Get the names of files in and below a given folder. 
classdef FileList < handle 
    properties (SetAccess = private, GetAccess = public) 
        dirName 
        % fileNames is a cell vector holding file names. 
        fileNames 
        nFiles = 0 
    end 
    properties (Constant, GetAccess = private) 
        % Pre-allocated fileNames length. 
        FILENAMES_LENGTH = 100 
    end 
    methods (Access = public) 
        % Constructor method. 
        function fList = FileList(dirName) 
            if dirName(end) == '\' % Handle the case for a root directory. 
                dirName = dirName(1:end-1); 
            end 
            fList.dirName = dirName; 
            fList.clear(); 
        end 
         
        % Clear the fileNames collected. 
        function clear(fList) 
            fList.nFiles = 0; 
            fList.fileNames = cell(fList.FILENAMES_LENGTH, 1); 
        end 
         
        % Collect file names found in the dirName. 
        function collectDirFiles(fList) 
            fList.clear(); 
            dirStruct = dir(fList.dirName); 
            for i = 1:numel(dirStruct);  
                fileName = dirStruct(i).name; 
                if dirStruct(i).isdir || fileName(1) == '.' 
                    continue; 
                else 
                    % Add file to the guiList. 
                    fullName = strcat(fList.dirName, '\', fileName); 
                    fList.addFile(fullName); 
                end 
            end 
        end 
         
        % Return the collected file names. 
        function files = getFileNames(fList) 
            if fList.nFiles > 0 
                files = fList.fileNames(1:fList.nFiles); 
            else 
                files = {}; 
            end 
        end 
         
        % Collect file names found in and below the dirName folder. 
        function collectSubFiles(fList) 
            fList.clear(); 
            fList.addFilesRecursively(fList.dirName); 
        end 
         
        % Collect folders found in and below the dirName folder. 
        function collectSubFolders(fList) 
            fList.clear(); 
            fList.addFoldersRecursively(fList.dirName); 
        end 
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    end 
     
    methods (Access = private) 
        % Add a file to fileNames. 
        function addFile(fList, fullName) 
            fList.nFiles = fList.nFiles + 1; 
            if fList.nFiles > length(fList.fileNames) 
                fList.fileNames = cat(1, fList.fileNames, cell(fList.FILENAMES_LENGTH, 1)); 
            end 
            fList.fileNames{fList.nFiles} = fullName; 
        end 
         
        % Go through nested folders recursively and store the file names. 
        function addFilesRecursively(fList, subDirName) 
            dirStruct = dir(subDirName); 
            for i = 1:numel(dirStruct) 
                shortName = dirStruct(i).name; 
                fullName = strcat(subDirName, '\', shortName); 
                % If a directory is encountered, then act recursively. 
                if dirStruct(i).isdir 
                    if strcmp(shortName, '.') || strcmp(shortName, '..') 
                        continue; 
                    end 
                    fList.addFilesRecursively(fullName); 
                % If a file is encountered, then add it to fileNames. 
                else 
                    if shortName(1) == '.' 
                        continue; 
                    end 
                    fList.addFile(fullName); 
                end 
            end 
        end 
         
        % Go through nested folders recursively and store their names. 
        function addFoldersRecursively(fList, subDirName) 
            dirStruct = dir(subDirName); 
            for i = 1:numel(dirStruct) 
                shortName = dirStruct(i).name; 
                fullName = strcat(subDirName, '\', shortName); 
                % If a directory is encountered, then act recursively. 
                if dirStruct(i).isdir 
                    if strcmp(shortName, '.') || strcmp(shortName, '..') 
                        continue; 
                    end 
                    fList.addFile(fullName); 
                    fList.addFoldersRecursively(fullName); 
                % If a file is encountered, then add it to fileNames. 
                else 
                    continue; 
                end 
            end 
        end 
    end 
end 
 
% Calculate the SUV factor for a PET image series, represented by the Dicom 
% slice 'dcmFileName'. 
 
function suvFactor = getSuvFactor(dcmFileName) 
    % Get Dicom header structure. 
    try 
        dcmInfo = dicominfo(dcmFileName); 
    catch %#ok<CTCH> 
        suvFactor = 0; 
        return; 
    end 
     
    if ~strcmp(dcmInfo.Modality, 'PT') 
        suvFactor = 0; 
        return; 
    end 
     
    if ~strcmp(dcmInfo.DecayCorrection, 'START') 
        error('Image is not decay corrected to START'); 
    end 
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    % Get relevant header fields. 
    halfLifeSecs = dcmInfo.RadiopharmaceuticalInformationSequence.Item_1.RadionuclideHalfLife; 
    injectionTimeStr = dcmInfo.RadiopharmaceuticalInformationSequence.Item_1.RadiopharmaceuticalStartTime; 
    scanStartTimeStr = dcmInfo.SeriesTime; 
    injectedDoseBq = dcmInfo.RadiopharmaceuticalInformationSequence.Item_1.RadionuclideTotalDose; 
    patientWeight = dcmInfo.PatientWeight; 
     
    % Get time between injection and scan start. 
    injectionTimeVec = datevec(datenum(injectionTimeStr, 'HHMMSS')); 
    scanStartTimeVec = datevec(datenum(scanStartTimeStr, 'HHMMSS')); 
    preScanTimeSecs = (scanStartTimeVec - injectionTimeVec) * [0; 0; 0; 3600; 60; 1]; 
     
    % Calculate SUV. 
    preScanDecayFactor = exp(log(2) / halfLifeSecs * preScanTimeSecs); 
    suvFactor = preScanDecayFactor * patientWeight / injectedDoseBq * 1000; 
end 
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8.2 Appendix 2: SUV PEAK Location Script 
# Python script for sweeping through an assigned volume and finding the highest average voxel number is a cubic mm sphere 
from nifti import * 
from numpy import * 
#import pdb 
#pdb.set_trace() 
#import subprocess 
#import os 
#from decimal import * 
study_participant = "GL33MO" 
CMET_10 = NiftiImage('D:/VM_shared/numpy/GL33MO_CMET_PET_10_SUV_2_MNI_T2_mutualinfo.nii.gz') 
CMET_20 = NiftiImage('D:/VM_shared/numpy/GL33MO_CMET_PET_20_SUV_2_MNI_T2_mutualinfo.nii.gz') 
CMET_30 = NiftiImage('D:/VM_shared/numpy/GL33MO_CMET_PET_30_SUV_2_MNI_T2_mutualinfo.nii.gz') 
CMET_40 = NiftiImage('D:/VM_shared/numpy/GL33MO_CMET_PET_40_SUV_2_MNI_T2_mutualinfo.nii.gz') 
 
FLT_15 = NiftiImage('D:/VM_shared/numpy/GL33MO_FLT_PET_15_SUV_2_MNI_T2_mutualinfo.nii.gz') 
FLT_75 = NiftiImage('D:/VM_shared/numpy/GL33MO_FLT_PET_75_SUV_2_MNI_T2_mutualinfo.nii.gz') 
 
corner_mask = NiftiImage('D:/VM_shared/numpy/bottom_corner_mask.nii.gz') 
 
cmet_images = [CMET_10, CMET_20, CMET_30, CMET_40] 
flt_images = [FLT_15, FLT_75] 
 
 
# bottom_corner.txt is the location of each voxel in a 
# MNI 152 1mm template sized image that would constitute 
# a 6mm sphere sitting in the "origin" corner 
 
# read the input file into a list of lines of text 
input_coords = open("D:/VM_shared/numpy/bottom_corner.txt", "r").readlines() 
# now walk through that list, splitting each line in to 3 coordinates 
# and converting each to an integer 
 
sphere = [ [int(values[0]), int(values[1]), int(values[2])] for values in [aline.split() for aline in input_coords] ] 
# sphere is now a list, each element of which is the (x,y,z) coo-rdinate of a voxel in the sphere. 
 
#output = open("D:/VM_shared/numpy/bottom_corner.txt", "w") 
#for x in range(0,20): 
 #for y in range (0,20): 
 # for z in range (0,20): 
 #  if corner_mask.data[z,y,x] == 1: 
    #print(z,y,x) 
 #   output.write("%s %s %s\n" % (z,y,x)) 
    #print(corner_mask.data[z,y,x]) 
     
    # instead of reading the 1cm sphere values in from a text file 
    # try running the previous bit of code and saving each datapoint as a variable or 
something, then recalling for each iteration. 
  
 
dict = {} 
#-----------------------------------------------------CMET------------------------------------------------------------ 
for cmet_image in cmet_images: 
 # specify a search volume for this individual 
 cmet_x_min = 90; cmet_x_max = 131 
 cmet_y_min = 124; cmet_y_max = 191 
 cmet_z_min = 64; cmet_z_max = 145 
 SUV_PEAK_list = list() 
 SUV_PEAK_list_with_coords = list() 
 
# move the sphere from bottom_corner.txt around all locations inside the search volume to get the average uptake at all points 
 for x in range (cmet_x_min,cmet_x_max): 
  for y in range (cmet_y_min,cmet_y_max): 
   for z in range (cmet_z_min,cmet_z_max): 
    voxel_count=0 
    for voxel in sphere: 
     voxel_count=voxel_count+1 
     x_coord = voxel[0] + z 
     y_coord = voxel[1] + y 
     z_coord = voxel[2] + x 
     dict["current_voxel_number" + str(voxel_count)] = 
cmet_image.data[x_coord, y_coord, z_coord] 
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    voxel_sum = dict["current_voxel_number" + str(voxel_count-0)] + 
dict["current_voxel_number" + str(voxel_count-1)] 
    for i in range(2,925): 
     voxel_sum = dict["current_voxel_number" + str(voxel_count-i)] + 
voxel_sum 
     #print (str(voxel_count-924)) 
    #print(voxel_sum) 
    SUV_PEAK = voxel_sum / 925 
     
    #print (x+6, y+6, z+6, SUV_PEAK) 
    SUV_PEAK_list.append(SUV_PEAK) 
    SUV_PEAK_list_with_coords.append(x+6) 
    SUV_PEAK_list_with_coords.append(y+6) 
    SUV_PEAK_list_with_coords.append(z+6) 
    SUV_PEAK_list_with_coords.append(SUV_PEAK) 
 
 #find out what SUV_PEAK is, print out the value and the location of the sphere centre 
 
 SUV_PEAK_value = max(SUV_PEAK_list) 
 SUV_PEAK_big_list_location = SUV_PEAK_list_with_coords.index(SUV_PEAK_value) 
 
 x_coordinate_list_location = SUV_PEAK_big_list_location-3 
 x_coordinate_value = SUV_PEAK_list_with_coords[x_coordinate_list_location] 
 
 y_coordinate_list_location = SUV_PEAK_big_list_location-2 
 y_coordinate_value = SUV_PEAK_list_with_coords[y_coordinate_list_location] 
 
 z_coordinate_list_location = SUV_PEAK_big_list_location-1 
 z_coordinate_value = SUV_PEAK_list_with_coords[z_coordinate_list_location] 
  
 #CMET_ = pet_image.filename[26:31] 
 #time = pet_image.filename[35:37] 
  
 CMET_ = cmet_image.filename[26:31] 
 cmet_time = cmet_image.filename[35:37] 
  
  
 print(study_participant, "%s%s " %(CMET_,cmet_time), 'SUV Peak Data' ) 
 print("coordinates: ", x_coordinate_value, y_coordinate_value, z_coordinate_value, " SUV_PEAK: ", 
SUV_PEAK_value) 
 print(' ') 
 
 
 # write out text files of both lists 
  
 with open("D:/VM_shared/numpy/%s_%s%s_SUV_PEAK_values_only.txt" 
%(study_participant,CMET_,cmet_time), "w") as file: 
   for item in SUV_PEAK_list: 
     print>>file, item 
 
 with open("D:/VM_shared/numpy/%s_%s%s_SUV_PEAK_values_with_coords.txt" 
%(study_participant,CMET_,cmet_time), "w") as file2: 
   for item2 in SUV_PEAK_list_with_coords: 
     print>>file2, item2 
 
      
#-----------------------------------------------FLT---------------------------------------------------------------- 
for flt_image in flt_images: 
 
 flt_x_min = 90; flt_x_max = 131 
 flt_y_min = 124; flt_y_max = 191 
 flt_z_min = 64; flt_z_max = 145 
 SUV_PEAK_list = list() 
 SUV_PEAK_list_with_coords = list() 
 
 
 for x in range (flt_x_min,flt_x_max): 
  for y in range (flt_y_min,flt_y_max): 
   for z in range (flt_z_min,flt_z_max): 
    voxel_count=0 
    for voxel in sphere: 
     voxel_count=voxel_count+1 
     x_coord = voxel[0] + z 
     y_coord = voxel[1] + y 
     z_coord = voxel[2] + x 
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     dict["current_voxel_number" + str(voxel_count)] = 
flt_image.data[x_coord, y_coord, z_coord] 
     
    voxel_sum = dict["current_voxel_number" + str(voxel_count-0)] + 
dict["current_voxel_number" + str(voxel_count-1)] 
    for i in range(2,925): 
     voxel_sum = dict["current_voxel_number" + str(voxel_count-i)] + 
voxel_sum 
     #print (str(voxel_count-924)) 
    #print(voxel_sum) 
    SUV_PEAK = voxel_sum / 925 
     
    #print (x+6, y+6, z+6, SUV_PEAK) 
    SUV_PEAK_list.append(SUV_PEAK) 
    SUV_PEAK_list_with_coords.append(x+6) 
    SUV_PEAK_list_with_coords.append(y+6) 
    SUV_PEAK_list_with_coords.append(z+6) 
    SUV_PEAK_list_with_coords.append(SUV_PEAK) 
 
 #find out what SUV_PEAK is, print out the value and the location of the sphere centre 
 
 SUV_PEAK_value = max(SUV_PEAK_list) 
 SUV_PEAK_big_list_location = SUV_PEAK_list_with_coords.index(SUV_PEAK_value) 
 
 x_coordinate_list_location = SUV_PEAK_big_list_location-3 
 x_coordinate_value = SUV_PEAK_list_with_coords[x_coordinate_list_location] 
 
 y_coordinate_list_location = SUV_PEAK_big_list_location-2 
 y_coordinate_value = SUV_PEAK_list_with_coords[y_coordinate_list_location] 
 
 z_coordinate_list_location = SUV_PEAK_big_list_location-1 
 z_coordinate_value = SUV_PEAK_list_with_coords[z_coordinate_list_location] 
  
 #CMET_ = pet_image.filename[26:31] 
 #time = pet_image.filename[35:37] 
  
 FLT_ = flt_image.filename[26:30] 
 flt_time = flt_image.filename[34:36] 
  
  
 print(study_participant, "%s%s " %(FLT_,flt_time), 'SUV Peak Data' ) 
 print("coordinates: ", x_coordinate_value, y_coordinate_value, z_coordinate_value, " SUV_PEAK: ", 
SUV_PEAK_value) 
 print(' ') 
 
 
 # write out text files of both lists 
  
 with open("D:/VM_shared/numpy/%s_%s%s_SUV_PEAK_values_only.txt" %(study_participant,FLT_,flt_time), 
"w") as file: 
   for item in SUV_PEAK_list: 
     print>>file, item 
 
 with open("D:/VM_shared/numpy/%s_%s%s_SUV_PEAK_values_with_coords.txt" 
%(study_participant,FLT_,flt_time), "w") as file2: 
   for item2 in SUV_PEAK_list_with_coords: 
     print>>file2, item2      
 
      
# writing out nifti images showing the search area 
 
for x in range (0,182): 
 for y in range (0,218): 
  for z in range (0,182): 
    
   CMET_10.data[z, y, x]=0 
  
for x in range (cmet_x_min,cmet_x_max): 
 for y in range (cmet_y_min,cmet_y_max): 
  for z in range (cmet_z_min,cmet_z_max): 
    
   CMET_10.data[z, y, x]=1 
    
    
 
CMET_ = CMET_10.filename[26:31] 
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CMET_10.save('D:/VM_shared/numpy/%s_%sPERCIST_search_area.nii.gz' %(study_participant,CMET_))  
    
      
for x in range (0,182): 
 for y in range (0,218): 
  for z in range (0,182): 
    
   FLT_15.data[z, y, x]=0 
  
for x in range (flt_x_min,flt_x_max): 
 for y in range (flt_y_min,flt_y_max): 
  for z in range (flt_z_min,flt_z_max): 
    
   FLT_15.data[z, y, x]=1 
 
 
 
FLT_ = FLT_15.filename[26:30] 
 
 
FLT_15.save('D:/VM_shared/numpy/%s_%sPERCIST_search_area.nii.gz' %(study_participant,FLT_))  
    
      
#output.write("%s %s %s\n" % (z,y,x)) 
 
#all_SUV_PEAK_values_with_coords = open("D:/VM_shared/numpy/CMET_10_SUV_PEAK_values_with_coords.txt", "w") 
#all_SUV_PEAK_values_with_coords.write(SUV_PEAK_list_with_coords) 
 
 
  
  
 #output = open("D:/VM_shared/numpy/corner_output.txt", "w") 
  
  
  
  
  
 #subprocess.call(["fslview /usr/local/fsl/data/standard/MNI152_T1_2mm.nii.gz"]) 
  
 
# flirt_command = 'flirt -in /usr/local/fsl/data/standard/MNI152_T1_2mm.nii.gz -out flirted_%s.nii.gz -ref 
/usr/local/fsl/data/standard/MNI152_T1_1mm.nii.gz -dof 6 -v' % count 
 #print(flirt_command) 
#os.system() 
 
 
 #flirt_command_2 = 'flirt -in /usr/local/fsl/data/standard/MNI152_T1_2mm.nii.gz -out flirted_%s.nii.gz -ref 
/usr/local/fsl/data/standard/MNI152_T1_1mm.nii.gz -dof 6 -v -omat flirted_%s.mat' % (count, count2) 
 #print(flirt_command_2) 
 
 #os.system(flirt_command_2) 
 #os.system("sh bash_script") # to run a bash script called bash_script 
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8.3 Appendix 3: Bootstrap Resampling Script 
 
The bias corrected percentile method of bootstrap resampling used in this body of 
work was based on the description in (Efron and Tibshirani 1993).   
 
The “Resampling stats in Excel” add in (http://www.resample.com/download-excel/) 
was used to create 1000 columns of numbers that represent bootstrap iterations of the 
data. This array was saved as a text file and then called into Matlab, where the 
following script was used to break it up into 1000 separate files: 
 
for i = 1:1000 
 filename = num2str(i) 
 A = untitled(i,1:40) 
 dlmwrite([‘/mnt/hgfs/VM_shared/’filename’.txt’],A,’delimiter’,’’,’newline’,’pc’) 
end 
 
These text files are then called by a perl script, which creates a mask based on each 
of the iterations by taking individual subject’s hippocampal regions and summing 
them using the FSL routine fslmaths. 
 
#!/usr/bin/perl -w 
use strict; # keep these magical incantations 
$|++;   # they make Perl work better ... 
 
use File::Copy; 
 
 
# get a list of text files in the iterations directory 
my $iterationlisting = `ls iterations/*.txt`; 
 
#print "Iteration listing:\n$iterationlisting"; 
 
 
my @iterationlist = split/\n/,$iterationlisting; 
 
my $iterationNo = 1; 
my $outputDir = "permutations"; 
my $maskDir = "FSL_masks"; 
 
foreach my $iterationFileName (@iterationlist) { 
 print "Permutation $iterationNo\n"; 
 
 my $fh; 
 open $fh, $iterationFileName or die "cannot open $iterationFileName\n"; 
 my $maskNumbers = <$fh>; 
 chomp($maskNumbers); 
  
 my @maskList = split(" ",$maskNumbers); 
  
 my $iterationFileName = $outputDir."/p".$iterationNo.".nii.gz"; 
 my $maskFileName = $maskDir."/".$maskList[0].".nii.gz"; 
 
 copy($maskFileName, $iterationFileName) or die "Could not copy $maskFileName\n"; 
  
 my $nMasks = @maskList; 
 for (my $i=1;$i < $nMasks; $i++) { 
  my $maskFileName = "FSL_masks/".$maskList[$i]; 
   
#  print "*** $iterationFileName -add $maskFileName $iterationFileName \n"; 
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  `fslmaths $iterationFileName -add $maskFileName $iterationFileName`; 
   
 } 
 
  
  
 $iterationNo++; 
} 
 
 
Jackknife iteration masks and differing percentage overlap masks were made using 
bash scripts, the below example is a script used to make jackknife mask iterations: 
 
#!/bin/bash 
 
cd  /mnt/hgfs/VM_shared/GB/jackknife_iterations_new 
 
 
 
 
for i in 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 
43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 
84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 
do 
 
 mkdir $i'_percent_mask' 
 echo '*********************************************************************' 
 echo '**************************'$i' percent ******************************' 
 echo '*********************************************************************' 
 
         for j in 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 
41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 
82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 
  do 
 
     
  fslmaths '/mnt/hgfs/VM_shared/GB/percentage_masks/binary/'$i'_percent_mask.nii.gz' -sub 
'/mnt/hgfs/VM_shared/GB/FSL_masks/'$j'.nii.gz' 
'/mnt/hgfs/VM_shared/GB/jackknife_iterations_new/'$i'_percent_mask/'$i'_percent_jackknife_'$j'.nii.gz' 
                fslmaths '/mnt/hgfs/VM_shared/GB/jackknife_iterations_new/'$i'_percent_mask/'$i'_percent_jackknife_'$j'.nii.gz' -
bin '/mnt/hgfs/VM_shared/GB/jackknife_iterations_new/'$i'_percent_mask/'$i'_percent_jackknife_'$j'_bin.nii.gz' 
  fslstats 
'/mnt/hgfs/VM_shared/GB/jackknife_iterations_new/'$i'_percent_mask/'$i'_percent_jackknife_'$j'_bin.nii.gz' -V | tee -a 
'/mnt/hgfs/VM_shared/GB/jackknife_iterations_new/'$i'_percent_mask/jackknife_summary.txt'        
         done 
done 
 
Finally, an excel spreadsheet is used to perform the actual BCa calculations. A new 
tab is created for each variation in overlap, and a result is shown that determines 
whether or not the mask is within the 95% BCa confidence limit and therefore 
considred “stable”. The macro used to call in each iteration’s data to the sheet is 
below: 
 
Function bootstrap_percentile_calculator() 
 
' open .txt file with all of the ACTUAL (from the initial data, not from a bootstrap interation) 
' values for the voxels contained in each mask 
 
Workbooks.OpenText Filename:="G:\bootstrap_new\percentage_masks\actual_percentage_mask_overlap_values.txt", _ 
Origin:=xlMSDOS, StartRow:=1, DataType:=xlDelimited, TextQualifier:= _ 
xlDoubleQuote, ConsecutiveDelimiter:=True, Tab:=True, Semicolon:=False, _ 
Comma:=False, Space:=False, Other:=False, FieldInfo:=Array(Array(1, 1), _ 
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Array(2, 1)), TrailingMinusNumbers:=True 
 
Dim i As Double 
For i = 5 To 10 Step 2.5 
' NOTE: THIS USUALLY FAILS AT VERY LOW OR VERY HIGH PERCENTAGE VALUES, DUE TO THE ACTUAL 
NUMBER OF 
' VOXELS IN THE PERCENTAGE OVERLAP MASK FALLING OUTSIDE OF THE BOOTSTRAP CONFIDENCE 
INTERVAL 
 ' copy a tab for the new data to be pasted into 
    Windows("BCA_method.xls").Activate 
    Sheets("dummy_worksheet").Select 
    Sheets("dummy_worksheet").Copy Before:=Sheets(1) 
    Sheets("dummy_worksheet (2)").Select 
    Sheets("dummy_worksheet (2)").Name = "" & i & "_percent_mask" 
    Columns("C:C").Select 
    Selection.ClearContents 
    Columns("H:H").Select 
    Selection.ClearContents 
     
' open .txt file with the bootstrap mask data inside for this mask 
    Workbooks.OpenText Filename:="G:\bootstrap_new\stats\" & i & "_percent_mask.txt", _ 
    Origin:=xlMSDOS, StartRow:=1, DataType:=xlDelimited, TextQualifier:= _ 
    xlDoubleQuote, ConsecutiveDelimiter:=True, Tab:=False, Semicolon:=False, _ 
    Comma:=False, Space:=True, Other:=False, FieldInfo:=Array(Array(1, 1), _ 
    Array(2, 1)), TrailingMinusNumbers:=True 
     
' copy bootstrap iteration mask volume values from .txt file into calc worksheet 
 
    Windows("" & i & "_percent_mask.txt").Activate 
    Range("A1:A1000").Select 
    Selection.Copy 
    Windows("BCA_method.xls").Activate 
    Sheets("" & i & "_percent_mask").Select 
    Range("C3:C1002").Select 
    ActiveSheet.Paste 
    Range("H1:H1000").Select 
    ActiveSheet.Paste 
' sort the values in column H from lowest to highest (this is how it picks the .025 and .975 percentile points) 
    Selection.Sort Key1:=Range("H1000"), Order1:=xlAscending, Header:=xlGuess _ 
    , OrderCustom:=1, MatchCase:=False, Orientation:=xlTopToBottom, _ 
    DataOption1:=xlSortNormal 
     
    Windows("" & i & "_percent_mask.txt").Activate 
    ActiveWindow.Close 
     
' take actual number of voxels from the appropriate mask from the .txt file and paste into calc worksheet 
    Windows("actual_percentage_mask_overlap_values.txt").Activate 
    For Each c In Worksheets("actual_percentage_mask_overlap_").Range("A1:A101") 
        If c.Value = i Then 
             c.Select 
             ActiveCell.Offset(0, 1).Select 
             Selection.Copy 
             Windows("BCA_method.xls").Activate 
             Sheets("" & i & "_percent_mask").Select 
             Range("C2").Select 
             ActiveSheet.Paste 
         End If 
    Next c 
         
' open .txt file with the jackknife iteration data inside for this mask for calc of theta(.) 
    Workbooks.OpenText Filename:="G:\bootstrap_new\jackknife_iterations\" & i & "_percent_mask.txt", _ 
    Origin:=xlMSDOS, StartRow:=1, DataType:=xlDelimited, TextQualifier:= _ 
    xlDoubleQuote, ConsecutiveDelimiter:=True, Tab:=False, Semicolon:=False, _ 
    Comma:=False, Space:=True, Other:=False, FieldInfo:=Array(Array(1, 1), _ 
    Array(2, 1)), TrailingMinusNumbers:=True 
     
     
' copy jackknife iteration data into worksheet for calculation of theta(.) 
 
    Windows("" & i & "_percent_mask.txt").Activate 
    Range("A1:A40").Select 
    Selection.Copy 
    Windows("BCA_method.xls").Activate 
    Sheets("" & i & "_percent_mask").Select 
    Range("Q2:Q41").Select 
    ActiveSheet.Paste 
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    Range("Q2:Q41").HorizontalAlignment = xlCenter 
    Windows("" & i & "_percent_mask.txt").Activate 
    ActiveWindow.Close 
 
' copy values from the H column to the cells that show the percentile ends 
  
    Windows("BCA_method.xls").Activate 
    Sheets("" & i & "_percent_mask").Select 
    Dim low As Integer 
    Dim high As Integer 
    low = Cells(34, "L").Value 
    If low >= 1 And low <= 1000 Then 
        Range("H" & low & "").Select 
        Selection.Copy 
        Range("L36").Select 
        ActiveSheet.Paste 
        Range("L36").HorizontalAlignment = xlCenter 
     
        high = Cells(35, "L").Value 
        Range("H" & high & "").Select 
        Selection.Copy 
        Range("L37").Select 
        ActiveSheet.Paste 
        Range("L37").HorizontalAlignment = xlCenter 
         
     Else 
     End If 
      
    If low = 0 Then 
        Range("H1").Select 
        Selection.Copy 
        Range("L36").Select 
        ActiveSheet.Paste 
        Range("L36").HorizontalAlignment = xlCenter 
     
        high = Cells(35, "L").Value 
        Range("H" & high & "").Select 
        Selection.Copy 
        Range("L37").Select 
        ActiveSheet.Paste 
        Range("L37").HorizontalAlignment = xlCenter 
         
     Else 
     End If 
      
Next i 
 
Windows("actual_percentage_mask_overlap_values.txt").Activate 
ActiveWindow.Close 
End Function 
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8.4 Appendix 4: Pons Normalisation Script 
 
//  ImageJ Macro for extracting mean values for each slice in the pons rectangular prism in MNI space 
// The pons runs from slice 7 to 12, the makePolygon function describes the area in each slice 
// creates a text file with a 6 by 2 matrix 
// that contains the following 
// Slice number (Z coord) :  mean voxel number 
// // Slice number (Z coord) :  mean voxel number etc for each of the 6 slices 
// this can then be read into matlab to get the mean voxel number for the pons in an image 
dir1 =getDirectory("Choose Source Directory for ROI_filled ");  
list1 = getFileList(dir1); 
for (i=0 ; i<list1.length; i++) {                                      // this is to make sure that it only gets the folders that contain the images 
files 
 //open(dir1+list1[i]); 
 //if (endsWith(list1[i],"_func_2_FSL_T1_MNI.nii.gz")) { 
 open(dir1+list1[i]+'func_2_MNI.nii.gz'); 
 gb = getInfo("image.filename"); 
 gb1 = substring(list1[i],0,4); 
 print(list1[i]+"_"+gb); 
 // now set rectangles on the correct slices and do the maths to do the scaling 
 setSlice(18); 
 makeRectangle(40, 49, 11, 6); 
 getStatistics(area, mean18, min, max, std, histogram); 
 print("mean18" + " " + mean18); 
 setSlice(19); 
 makeRectangle(40, 49, 11, 6); 
 getStatistics(area, mean19, min, max, std, histogram); 
 print("mean19" + " " + mean19); 
 setSlice(20); 
 makeRectangle(40, 49, 11, 6); 
 getStatistics(area, mean20, min, max, std, histogram); 
 print("mean20" + " " + mean20); 
 setSlice(21); 
 makeRectangle(40, 49, 11, 6); 
 getStatistics(area, mean21, min, max, std, histogram); 
 print("mean21" + " " + mean21); 
 setSlice(22); 
 makeRectangle(40, 49, 11, 6); 
 getStatistics(area, mean22, min, max, std, histogram); 
 print("mean22" + " " + mean22); 
 setSlice(23); 
 makeRectangle(40, 49, 11, 6); 
 getStatistics(area, mean23, min, max, std, histogram); 
 print("mean23" + " " + mean23); 
 meansum = mean18 + mean19 + mean20 + mean21 + mean22 + mean23; 
 print(meansum); 
 mean = meansum / 6; 
 print("pons mean =  " + mean); 
 calfactor = 10000/mean; 
 print("calfactor =  " + calfactor); 
 print("scaled pons mean =  " + calfactor*mean); 
 print(" "); 
 makeRectangle(0, 0, 91, 109); 
 run("Multiply...", "value=calfactor stack"); 
 run("Flip Horizontally", "stack");                       //these two lines get it back in the correct orientation before resaving 
 run("Rotate... ", "angle=180 grid=1 interpolation=Bicubic stack"); 
 run("Analyze 7.5...", "save="+dir1+list1[i]+"func_2_MNIscaled"); 
// selectWindow(gb); 
 close(); 
// gb1 = substring(gb,0,4);   
// selectWindow("Log"); 
// saveAs("Text", "D:\\Analyze\\32_bit\\pons\\"+gb1+".txt"); 
// selectWindow("Log"); 
// run("Close"); 
 
 //}else{  
 //} 
} 
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8.5 Appendix 5: Hippocampal Mask Volume Sampling 
 
// ImageJ macro for sampling a masked region in a PET image, return a list of voxel number from within the volume in a text 
file.  
//PONS NORMALISATION 
// 
// Imports each warped PET, records the average counts within the pons (approximate area outlined) on the 2mm  
// res T1 FSL template, then scales the image so that the average pons counts = 10 000. Saves the scaled image. 
// Only works when the directory tree looks like this:    
//                   some dir/ 
// 
//  AD/                                             HC/ 
// 
//                         patient1/              patient2/  etc              patient1/                 patient2/  etc 
// 
//             image_title.nii.gz               image_title.nii.gz                  image_title.nii.gz                           image_title .nii.gz 
// 
//AND when the images have been warped to the FSL T1 2mm res template. warping to another template will 
//require different slices and areas to be used for the pons and a different rectangle to use to identify the whole slice for  
//rescaling. 
//EDIT: it also works for the SPM PET template as this is in very good alignment with the FSL T1 2mm MNI template and 
//has the same voxel size. 
// It also requires all the images of the same modality to have the same name 
 
dir1 =getDirectory("Choose Source Directory for AD images");  
list1 = getFileList(dir1); 
dir2 =getDirectory("Choose Source Directory for HC images");  
list2 = getFileList(dir2); 
dir3 =getDirectory("Choose Source Directory for MCI images");  
list3 = getFileList(dir3); 
 
//image_title=File.openDialog("pick a warped PET image"); 
image_title_1="func_2_MNI";                                   //image_title_1=substring(image_title,32,51); 
 
for (i=0 ; i<list1.length; i++) {                
 open(dir1+list1[i]+image_title_1+".nii.gz");                        
 setSlice(22); 
 makePolygon(40,49,40,52,42,54,49,54,51,52,51,49); 
 getStatistics(area, mean22, min, max, std, histogram); 
 setSlice(21); 
 makePolygon(40,49,40,52,42,54,49,54,51,52,51,49); 
 getStatistics(area, mean21, min, max, std, histogram); 
 setSlice(20); 
 makePolygon(40,49,40,51,42,53,49,53,51,51,51,49); 
 getStatistics(area, mean20, min, max, std, histogram); 
 setSlice(19); 
 makePolygon(40,49,43,52,48,52,51,49); 
 getStatistics(area, mean19, min, max, std, histogram); 
 setSlice(18);  
 makePolygon(41,49,43,52,48,52,50,49); 
 getStatistics(area, mean18, min, max, std, histogram); 
 setSlice(17); 
 makePolygon(41,49,43,51,47,51,49,49); 
 getStatistics(area, mean17, min, max, std, histogram); 
 meansum = mean22 + mean21 + mean20 + mean19 + mean18 + mean17 ; 
 mean = meansum / 6; 
 calfactor = 10000/mean; 
 makeRectangle(0, 0, 91, 109); 
 //the next line gets it back in the correct orientation before resaving 
 run("Multiply...", "value=calfactor stack");                       
 run("Flip Vertically", "stack"); 
 run("Analyze 7.5...", "save="+dir1+list1[i]+image_title_1+"_scaled"); 
 close(); 
} 
 
for (i=0 ; i<list2.length; i++) {                
 open(dir2+list2[i]+image_title_1+".nii.gz");       
 setSlice(22); 
 makePolygon(40,49,40,52,42,54,49,54,51,52,51,49); 
 getStatistics(area, mean22, min, max, std, histogram); 
 setSlice(21); 
 makePolygon(40,49,40,52,42,54,49,54,51,52,51,49); 
 129 
 
 getStatistics(area, mean21, min, max, std, histogram); 
 setSlice(20); 
 makePolygon(40,49,40,51,42,53,49,53,51,51,51,49); 
 getStatistics(area, mean20, min, max, std, histogram); 
 setSlice(19); 
 makePolygon(40,49,43,52,48,52,51,49); 
 getStatistics(area, mean19, min, max, std, histogram); 
 setSlice(18);  
 makePolygon(41,49,43,52,48,52,50,49); 
 getStatistics(area, mean18, min, max, std, histogram); 
 setSlice(17); 
 makePolygon(41,49,43,51,47,51,49,49); 
 getStatistics(area, mean17, min, max, std, histogram); 
 meansum = mean22 + mean21 + mean20 + mean19 + mean18 + mean17 ; 
 mean = meansum / 6; 
 calfactor = 10000/mean; 
 makeRectangle(0, 0, 91, 109); 
 run("Multiply...", "value=calfactor stack"); 
//the next line gets the image back in the correct orientation for FSL before resaving                       
 run("Flip Vertically", "stack"); 
 run("Analyze 7.5...", "save="+dir2+list2[i]+image_title_1+"_scaled"); 
 close(); 
} 
 
for (i=0 ; i<list3.length; i++) {                
 open(dir3+list3[i]+image_title_1+".nii.gz");       
 setSlice(22); 
 makePolygon(40,49,40,52,42,54,49,54,51,52,51,49); 
 getStatistics(area, mean22, min, max, std, histogram); 
 setSlice(21); 
 makePolygon(40,49,40,52,42,54,49,54,51,52,51,49); 
 getStatistics(area, mean21, min, max, std, histogram); 
 setSlice(20); 
 makePolygon(40,49,40,51,42,53,49,53,51,51,51,49); 
 getStatistics(area, mean20, min, max, std, histogram); 
 setSlice(19); 
 makePolygon(40,49,43,52,48,52,51,49); 
 getStatistics(area, mean19, min, max, std, histogram); 
 setSlice(18);  
 makePolygon(41,49,43,52,48,52,50,49); 
 getStatistics(area, mean18, min, max, std, histogram); 
 setSlice(17); 
 makePolygon(41,49,43,51,47,51,49,49); 
 getStatistics(area, mean17, min, max, std, histogram); 
 meansum = mean22 + mean21 + mean20 + mean19 + mean18 + mean17 ; 
 mean = meansum / 6; 
 calfactor = 10000/mean; 
 makeRectangle(0, 0, 91, 109); 
 run("Multiply...", "value=calfactor stack"); 
//the next line gets the image back in the correct orientation for FSL before resaving                       
 run("Flip Vertically", "stack"); 
 run("Analyze 7.5...", "save="+dir3+list3[i]+image_title_1+"_scaled"); 
 close(); 
} 
//CONVERTING PONS SCALED IMAGES TO NIFTI 
// 
//FSL only works with nifti but ImageJ only wants to save as analyze... 
 
// convert analyze files to nifti 
for (i=0 ; i<list1.length; i++) {  
 exec("mri_convert", dir1+list1[i]+image_title_1+"_scaled"+".img", dir1+list1[i]+image_title_1+"_scaled"+".nii.gz" 
); 
 } 
for (i=0 ; i<list2.length; i++) {  
 exec("mri_convert", dir2+list2[i]+image_title_1+"_scaled"+".img", dir2+list2[i]+image_title_1+"_scaled"+".nii.gz" 
); 
 } 
for (i=0 ; i<list3.length; i++) {  
 exec("mri_convert", dir3+list3[i]+image_title_1+"_scaled"+".img", dir3+list3[i]+image_title_1+"_scaled"+".nii.gz" 
); 
 } 
 
// delete analyze files 
for (i=0 ; i<list1.length; i++) {  
 exec("rm", dir1+list1[i]+image_title_1+"_scaled"+".img", dir1+list1[i]+image_title_1+"_scaled"+".hdr" ); 
 } 
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for (i=0 ; i<list2.length; i++) {  
 exec("rm", dir2+list2[i]+image_title_1+"_scaled"+".img", dir2+list2[i]+image_title_1+"_scaled"+".hdr" ); 
 } 
for (i=0 ; i<list3.length; i++) {  
 exec("rm", dir3+list3[i]+image_title_1+"_scaled"+".img", dir3+list3[i]+image_title_1+"_scaled"+".hdr" ); 
 } 
 
//MASKING THE SCALED PET IMAGES 
 
mask_title=File.openDialog("pick the mask image"); 
Dialog.create("Mask name input"); 
Dialog.addString("text to add to masked pet image to identify which mask was used:", ""); 
Dialog.show(); 
mask_suffix = Dialog.getString(); 
for (i=0 ; i<list1.length; i++) {  
 exec("fslmaths", mask_title, "-mul", dir1+list1[i]+image_title_1+"_scaled"+".nii.gz", 
dir1+list1[i]+image_title_1+"_scaled_"+mask_suffix+".nii.gz"  ); 
 } 
for (i=0 ; i<list2.length; i++) {  
 exec("fslmaths", mask_title, "-mul", dir2+list2[i]+image_title_1+"_scaled"+".nii.gz", 
dir2+list2[i]+image_title_1+"_scaled_"+mask_suffix+".nii.gz" ); 
 } 
for (i=0 ; i<list3.length; i++) {  
 exec("fslmaths", mask_title, "-mul", dir3+list3[i]+image_title_1+"_scaled"+".nii.gz", 
dir3+list3[i]+image_title_1+"_scaled_"+mask_suffix+".nii.gz" ); 
 } 
 
selectWindow("Log"); 
run("Close"); 
 
//EXTRACT AND RECORD HIPPOCAMPAL VOXELS FROM  THE MASKED SCALED PET IMAGES 
 
dir4 =getDirectory("Choose output directory for voxel count .txt files");  
File.makeDirectory(dir4+"AD"); 
dir5=dir4+"AD/"; 
File.makeDirectory(dir4+"HC"); 
dir6=dir4+"HC/"; 
File.makeDirectory(dir4+"MCI"); 
dir7=dir4+"MCI/"; 
for (i=0; i<list1.length; i++) { 
 open(dir1+list1[i]+image_title_1+"_scaled_"+mask_suffix+".nii.gz"); 
 gb = list1[i]; 
    w = getWidth(); 
     h = getHeight(); 
 s = nSlices(); 
 for (z=1; z<=s; z++){ 
  setSlice(z); 
       for (x=0; x<=w; x++) { 
            for (y=0; y<h; y++) {   
                v = getPixel(x, y); 
    if (v > 0){ 
      print("" +  v); 
    } else{ 
    } 
              } 
        } 
 } 
 selectWindow("Log"); 
 gb1 = substring(gb,0,4); 
 saveAs("Text", ""+dir5+gb1); 
 run("Close"); 
 close(); 
} 
 
for (i=0; i<list2.length; i++) { 
 open(dir2+list2[i]+image_title_1+"_scaled_"+mask_suffix+".nii.gz"); 
 gb = list2[i]; 
    w = getWidth(); 
     h = getHeight(); 
 s = nSlices(); 
 for (z=1; z<=s; z++){ 
  setSlice(z); 
       for (x=0; x<=w; x++) { 
            for (y=0; y<h; y++) {   
                v = getPixel(x, y); 
    if (v > 0){ 
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      print("" +  v); 
    } else{ 
    } 
              } 
        } 
 } 
 selectWindow("Log"); 
 gb1 = substring(gb,0,4); 
 saveAs("Text", ""+dir6+gb1); 
 run("Close"); 
 close(); 
} 
 
for (i=0; i<list3.length; i++) { 
 open(dir3+list3[i]+image_title_1+"_scaled_"+mask_suffix+".nii.gz"); 
 gb = list3[i]; 
    w = getWidth(); 
     h = getHeight(); 
 s = nSlices(); 
 for (z=1; z<=s; z++){ 
  setSlice(z); 
       for (x=0; x<=w; x++) { 
            for (y=0; y<h; y++) {   
                v = getPixel(x, y); 
    if (v > 0){ 
      print("" +  v); 
    } else{ 
    } 
              } 
        } 
 } 
 selectWindow("Log"); 
 gb1 = substring(gb,0,4); 
 saveAs("Text", ""+dir7+gb1); 
 run("Close"); 
 close(); 
} 
 
 
 
